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ABSTRACT
Recognizing the substantial public health impact of tobacco dependence (TD) and
consequent importance of reducing tobacco use, the United States Public Health
Service (USPHS) issues evidence based clinical practice guidelines (CPG) that urge
“clinicians and health care delivery systems to consistently identify and document
tobacco use status and treat every tobacco user seen in a health care setting”. The
latest guidelines, published in 2008, were written “in response to new, effective
clinical treatments for tobacco dependence” identified since 1999 and contain
strategies and recommendations designed to assist clinicians, administrators, insurers,
and purchasers in “delivering and supporting effective treatments for tobacco use and
dependence”. The guidelines state that, barring contraindication or insufficient study
in a specific sub-group, interventions for tobacco cessation are appropriate for all
individuals who use tobacco, including patients with medical co-morbidities. Specific
medical co-morbidities cited in the CPG for which pharmacologic interventions have
been shown effective include cancer. Moreover, continued smoking in cancer patients
can affect the pharmacokinetics of cancer treatments.
An important consideration for patients selected for treatment with smoking
cessation medication (SCM) is the duration of therapy or persistence with therapy as
these measures of medication adherence have been found to be associated with
treatment success in clinical trials. Another important factor to consider in assessing
SCM is recognition that tobacco dependence is a chronic disease that often requires
repeated interventions. Patient relapse to tobacco use following a period of abstinence
achieved with use of SCM is not unexpected.

Since the CPG serve as the definitive source to inform tobacco cessation practice
in the US, one would expect that epidemiologic studies of smoking cessation
medications (SCM) have been conducted in order to understand intervention use in
routine clinical practice, both in the overall population of tobacco dependent patients
and those with smoking related co-morbidities, such as cancer since epidemiologic
studies are a required early step in the process toward closing gaps in care.
However, literature search for population level studies in large representative
populations revealed few and most are derived from survey level data. Similarly,
literature search for studies of the use of SCM in patients with cancer returned few
results. Thus, real world studies describing the epidemiology of SCM in routine US
clinical practice are lacking. Though they are not without limitations, adequately
controlled observational studies using administrative healthcare claims data can
answer important questions in a relatively inexpensive and time-efficient manner.
This dissertation utilizes the manuscript format and has three main objectives:

1) To describe the pharmacoepidemiology of SCM among smokers identified
through CPT and ICD-9 codes to answer the question, “Who among smokers receives
pharmacologic treatment?”
2) To describe treatment persistence in tobacco dependent patients prescribed
SCM, repeat treatment with SCM and patient and prescriber characteristics associated
premature discontinuation and repeat therapy.

3) Evaluation of the use of SCM among tobacco dependent patients with smoking
related cancer diagnoses to answer the question, “Who receives pharmacologic
treatment and who doesn’t?”
The LifeLink™ Helath Plan Claims Database was employed to identify patients
diagnosed or counseled for tobacco cessation (index) during a one year period and
evaluate the use of SCM in the 1 year following the index date, rates of premature
discontinuation and repeat therapy as well as use of SCM in patients with smoking
related cancers.

Predictors of the use of SCM in tobacco dependent patients,

premature discontinuation and repeat therapy were assessed using logistic regression
models, controlling for pre-index patient and/or treatment characteristics. The same
was performed to identify predictors of SCM use in tobacco dependent patients with
smoking related cancer.
Major findings reported in the first manuscript are that approximately 11% of
newly diagnosed tobacco dependent patients received treatment within a year of
diagnosis and that the youngest and oldest age groups were less likely to receive SCM
than those at middle age. Of note, patients who may have had tobacco related comorbidities were less likely to receive treatment than those without. The study of
persistence and repeat therapy revealed that mean persistence was 36 days and that
>90% of patients discontinued SCM before 12 weeks of therapy, shorter than
recommendations. Patients under 50 years old and 65 years or older were more likely
to discontinue prematuredly than patients aged 50-58 years.

Few patients (5%)

repeated therapy ≥ 26 weeks following index. The final study of the use of SCM in
tobacco dependent patients with smoking related cancer revealed that tobacco

dependence of counseling/advice for smoking cessation in these patients was likely
coincident or following diagnosis of comorbidity. This finding was also noted in the
first study where pre-index mean Charlson Comorbidity was lower than the period
following diagnosis.
The 3 studies presented provide insight into the utility of using administrative
claims data to study patients who are tobacco dependent and their treatment with
SCM. Taken in their entirety, these studies’ findings contribute certain apparent
overarching themes and other important observations that may be useful to practicing
clinicians to highlight potential opportunities for treatment with SCM in patients who
may benefit most. First, it seems that the health system is identifying patients as
tobacco dependent co-incident with identification of other co-morbidity.

Earlier

intervention of management of tobacco dependence is likely the best strategy to aid
patients in quitting. Second, diagnosis or counseling by a hospital related practitioner
was associated with reduced likelihood of SCM treatment as an outpatient overall and
in patients with smoking related cancer. Hospitalization has been identified as an
opportune time for clinicians to intervene and offer assistance with smoking cessation.
Diagnosis by a therapeutic specialist was associated with lower likelihood of SCM use
and tobacco dependence can be a major contributor to risk of events often managed by
therapeutic area specialists, e.g., cardiologists and oncologists. Rates of treatment
with SCM by physician type is not widely described but literature reports and clinical
practice guidelines recommend that cardiologists and oncologists are well positioned
to assist patients in their quit attempts to reduce overall health risks.
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PREFACE
This thesis was written and formatted following the guidelines presented by the
University of Rhode Island Graduate School. It is written in the Manuscript Format
and is organized in three chapters: Epidemiology of smoking cessation medications in
the United States (Chapter 1), Persistence and Repeat Use of Smoking Cessation
Medications in the United States (Chapter 2), Use of Smoking Cessation Medications
in Tobacco Dependent Patients with Smoking Related Cancers (Chapter 3).
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Background
Smoking continues to be a leading contributor to morbidity and mortality in the
United States1,2(US) and intensive public health campaigns have been waged to assist
smokers’ quitting efforts and to educate clinicians as to the chronic relapsing nature of
tobacco dependence and assist their efforts in aiding their patients to quit. Leading US
based clinical practice guidelines for tobacco cessation recommend that smoking
cessation medications (SCM) be offered to all patients, excepting those with specific
contraindications or where evidence of efficacy may be lacking.3 Despite these broad
recommendations for employing SCM to aid smokers in quitting, little is known as to
the extent of their use, nor which patient characteristics may be associated with
prescription of such treatments.
Health-related databases, including claims databases, are an important data
source for research. One strength of these data is that they allow researchers to
examine medical care utilization as it occurs in routine clinical care or the “real
world”. These data sources can provide large study populations, long observation
periods and allow for examination of specific sub-populations.4 Though they are not
without limitations, adequately controlled observational studies using administrative
claims data can answer important questions in a relatively inexpensive and timeefficient manner.4 Of note, current estimates suggest that 87% of the US population
has health insurance coverage through employer sponsorship (48%), other private
insurance (6%) , Medicaid (16%), Medicare (15%) or other public insurance (2%).5
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Consequently, examination of nationwide US health plan data is expected to
reveal useful information regarding tobacco cessation treatment in routine clinical
practice. Few reports exist in the literature regarding the epidemiology of tobacco
cessation therapy in routine US clinical practice. Studies with a national focus
include those using national survey databases such as the National Health Interview
Survey and the National Ambulatory Medical Care Survey.6-8 Similar to Healthcare
Effectiveness Data and Information Set (HEDIS) measures, these databases typically
include self-reported smokers’ recall of whether assistance or advice to quit smoking
was given by a health care provider. Although these studies provide a broad
epidemiologic perspective, their results may be affected by recall bias.
Few studies have examined administrative claims data for the purpose of
understanding SCM use and examples include studies specific to varenicline and the
effect of a utilization management approach and patients’ copay on future dispensing
of any SCM.9,10 The aims of this research were to describe the
pharmacoepidemiology of SCM in newly identified tobacco dependent patients in
routine clinical practice in the US and to assess the patient and provider characteristics
associated with its prescribing.
Methods
This study employed a retrospective cohort design using de-identified data from
the LifeLink™ Health Plan Claims Database (formerly known as Pharmetrics) which
is comprised of commercial health plan information obtained from managed care plans
throughout the US. It is fully adjudicated medical and pharmaceutical claims for over
68 million unique patients from over 102 health plans across the U.S. (approximately
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16 million covered lives per year). The database includes both inpatient and
outpatient diagnoses (In International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] format) and procedures (in Current Procedure
Terminology [CPT-4] codes and Healthcare Common Procedure Coding System
[HCPCS] formats) as well as both retail and mail order prescription records.
Available data on prescription records include the National Drug Code (NDC) as well
as the quantity of the medication dispensed. Charge, allowed and paid amounts are
available for all services rendered, as well as dates of service for all claims.
Additional data elements include demographic variables (age, gender, geographic
region), insurance product type (e.g., HMO, PPO), payer type (e.g., commercial, selfpay), provider specialty, and start and stop dates of health-plan enrollment.

The sample consisted of patients aged 16-76 with a diagnosis code for tobacco use
disorder and/or CPT code for tobacco cessation counseling or advice (Appendix)
during the period July 2010 to June 2011 (index) (n=15,000). Patients with ICD-9,
CPT codes, or prescriptions related to tobacco dependence or treatment in the
lookback period January 2009 through June 2010 were excluded. Pre-index Charlson
Comorbidity Index (CCI) scores for each patient were calculated using the algorithm
develop by Quan, et al., through identification of ICD-9 codes related to 17
co-morbidity categories in the 12 month period prior to and 12 month period following
the index date (including index date) (Appendix). Weights specific to each comorbidity category were assigned and the CCI score calculated; higher scores indicate
greater co-morbidity.11
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Statistical Analysis
Descriptive statistics were used to describe demographic and clinical
characteristics and frequency of prescription of SCM defined as 1 or more claim for
varenicline, bupropion SR or NRT during the 1 year period following diagnosis for
tobacco use disorder or CPT code for tobacco cessation counseling, advice or
treatment. Demographic characteristics included patient age at index, gender,
geographic region of residence and insurance related factors such as payer type and
insurance product. Clinical characteristics included 12 months pre-index CCI score
and CCI categories. Provider characteristics included the practitioner type associated
with diagnosis of or counseling/advice for tobacco dependence.

Patients were categorized into one of two groups, those who were prescribed SCM
within 1 year of diagnosis and those who were not. Bivariate analyses including ttests for continuous variables and chi-square tests or Fisher’s Exact test for categorical
variables were used to analyze differences in characteristics of those patients receiving
SCM and those who did not. Assessment of factors associated with SCM prescription
was performed by conducting a series of univariate logistic regression equations. To
qualify for multivariate logistic regression, variables had to be associated with SCM
prescription in the univariate analyses (p<0.2) or be otherwise clinically important.
Multivariate logistic regression was used to assess relationships between the
independent variables of patient and provider characteristics and the dependent
variable of pharmacologic intervention for SC within a 1 year period following the
diagnosis of or procedure for tobacco use disorder. The model was created using a
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backward elimination process and the likelihood ratio test and AIC used to assess the
model at each step, removing least statistically significant covariates (p>0.05) with
each iteration and evaluating differences between full and reduced models for
statistical significance. In advance of model inclusion, parametric form of continuous
independent variables and multicollinearity among independent variables were
assessed.
Multicollinearity was assessed by regressing independent variables against the
independent variable of patient age at index. Main effects and two factor interactions
of independent variables found significant in the model were assessed. The HosmerLemeshow test was used to assess goodness of fit of the final model. The measure of
effect is presented as an odds ratio with corresponding 95% confidence intervals. All
analyses were conducted using SAS® Version 9.4 (SAS Institute, Cary, NC) with
statistical significance defined as p <0.05. Analyses were performed using a 2-tailed
alpha of 0.05 and 95% confidence intervals calculated.

Results
In total, 15,000 patients with ICD-9 or CPT codes indicative of tobacco
dependence disorder were identified (Figure 1). Mean (SD) age at diagnosis was
46.08 (14.46) years, 54.49% were female and 70.60% resided in the Midwest. (Table
1). Mean (SD) pre-index Charlson Co-morbidity Index (CCI) was 0.540 (±1.184)
with most patients having no Charlson co-morbidity (70.73%) and, of those with comorbidity, the most frequently observed was COPD (12.61%). Most (56.95%) were
diagnosed with or counseled for tobacco cessation by a general medicine practitioner
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and the majority of patients (79.27%) had commercial insurance (s 1,2). Of the
diagnosed sample, 1,621 (10.81%) had a prescription for SCM filled during the 1 year
post-index period (Figure 1). Varenicline was the most commonly prescribed agent
(69.46%) and bupropion SR the least commonly prescribed (4.38%), with NRT
formulations comprising 27.76% of SCM use (Figure 2).
In treated patients, mean (SD) age was 44.56 (12.52) years and the youngest and
oldest patients were least likely to be prescribed SCM while those aged 25-44 were
nearly twice as likely to receive SCM. Gender and geographic region were also
related to receiving SCM with females being more likely than males to have a
prescription for SCM (11.33% vs. 10.18%, p=0.0243) and patients residing in the
Midwest nearly 3 times more likely to receive SCM than those residing in the West.
Pre-index mean CCI score was lower in SCM treated patients than untreated (0.402 vs.
0.5571, p<0.0001) with SCM treatment occurring in >20% of tobacco dependent
patients with HIV/AIDS and approximately 10% of COPD patients. Less than 10% of
patients with other CCI categories received treatment. Patients with commercial and
Medicaid insurance types had the highest treatment rates (11.74% and 12.56%,
respectively) with <10% of patients with Medicare Supplemental or Medicare
Advantage receiving treatment.

The most common diagnosing practitioner type was the category of general
medicine (56.95%) and more patients (14.35%) were treated with SCM who were
diagnosed as tobacco dependent by a general medicine practitioner than any other
specialty. The lowest rates of SCM treatment patients were in those whose diagnosis
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was made by a hospital related physician (4.92%) or a therapeutic area specialist
(7.06%), though these were the second and third most common diagnosing practitioner
types (35.23% and 9.83%, respectively) (Table 3).
Multivariate logistic regression results indicated that patients with a pre-index comorbidity of cancer had reduced odds of receiving SC medication (OR 0.703, 95% CI
0.504-0.980). Compared to patients age 45-54, patients between 18-24 years had lower
likelihood of receiving SCM ( OR 0.539, 95% CI 0.430-0.677) as did patients >56
years (OR 0.616, 95% CI 0.528-0.718). Compared to those patients diagnosed by a
general medicine practitioner, those diagnosed or counseled for tobacco dependence
by a hospital related practitioner (OR 0.332, 95% CI 0.285-0.386), by a therapeutic
area specialist (OR 0.594, 95% CI 0.473-0.745) had lower likelihood of SC
medication prescription (Table 4). We found no association of gender, geographic
region or insurance related factors with prescription of SCM in the 1 year post-index.
Once you have the correct amount of content on the first page, you can then move
your cursor onto the next page of the template and add the rest of the content of the
chapter by either typing or copying and pasting.

Discussion
Clinical practice guidelines for tobacco cessation recommend that SCM be
offered to all tobacco dependent patients with few exceptions. However, little
information exists regarding the extent of SCM use in broad populations of tobacco
dependent persons in the US. This study observed that approximately 11% of those
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diagnosed or counseled for tobacco cessation (10.18% of males, 11.3% of
females) were prescribed SCM during the following year and the mean age (~46
years) was slightly older than or similar to that studied in recent clinical trials of SCM.
12 13 14

After controlling for covariates, the patient demographics of gender and

geographic region were not associated with SCM treatment. However, 18-24 and 5675 year olds had lower odds of receiving SCM than those aged 45-54, the age group
with the largest proportion of treated patients. Of note, the clinical factor of comorbid
cancer had a negative association, as did clinical settings of diagnosis other than
general medicine.
It is difficult to compare rates of SCM prescribing and recipient patient
characteristics to those reported in the current literature due to dissimilar study designs
and populations studied, however comparison of results from some studies is worth
noting. Huang, et al 15 used association rule mining methods to identify smokers in
the United Kingdom (UK) primary care and the characteristics of those who typically
do or do not receive SCM. The authors identified a population of smokers that was
46.7% male, of which 13.4% received a prescription for one or more SCM in 2008;
12.8% of males received SCM and 13.9% of females. Contrary to our finding that
gender was not associated with receipt of treatment, these authors found that females
were slightly more likely than males to receive SCM in multivariate analysis (OR
1.09, 95% CI 1.06-1.11). ). They also found that those in age groups > 30 years were
more likely to receive SCM than younger patients. Similarly, we found that the
youngest patients (<24 years) were less likely to receive SCM than those patients age
45-54, however we also found that the oldest patients (>56 years) had lower odds. Of

9

note, a recent policy statement by the American Academy of Pediatrics states that,
despite limited research in this age group, SCM is an option for tobacco-dependent
adolescents based on level of dependence and readiness to change.16 Also of note is a
recent literature review of SCM in older adults in which the authors report a dearth of
information regarding use in this population.17 More study of the use in SCM in the
youngest and oldest tobacco dependent patients is needed.
In the current study, patients with Medicaid and commercial insurance (primarily
employer base) had the highest rates of SCM use (12.56% and 11.74%, respectively)
while patients with Medicare Advantage had the lowest rate (5.08%). It should be
noted that during the study period, Medicare coverage of tobacco cessation services
may have been limited. In 2011, Medicare expanded coverage of tobacco cessation
counseling to any Medicare recipient who wanted to quit. Before then, these services
were limited to those who had a smoking-related illness or symptoms of such an
illness. Similar rates of pharmacy benefit (83.5%) as rates of commercial insurance
(~79.3%) were observed in this study and, while coverage specific to SCM is not
known, patients with a pharmacy benefit may be more likely to fill prescriptions than
those without.
Medicaid populations have a higher smoking rate than the general population18,19
which might explain higher treatment rates than other payer types. In addition,
coverage for SCM in Medicaid may be different than in other payer types. As of
2014, some SCM for some Medicaid enrollees were covered by all 50 states and the
District of Columbia, but coverage for all approved SCM products for all enrollees
was available in only 7 states. 20 Of note, in 2006, Massachusetts expanded coverage
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to include behavioral counseling and all FDA approved medications for tobacco
cessation for the Massachusetts Medicaid population and researchers found a decrease
in crude smoking rate after benefit initiation.21
Overall, comorbidity as assessed by CCI was low but mean CCI score was higher
in the follow up period compared to the 12 months pre-index. Mean pre-index CCI
was 0.540 and this increased by 34% to 0.724 in the follow up period. While still low,
the higher score in the follow up period suggests that diagnosis of or counseling for
tobacco cessation may have been coincident with a tobacco related diagnosis or other
health event. Additionally, the absence of any Charlson comorbidity pre-index was
observed in 70.73% of patients, but this proportion was lower in the follow up period
(60.55%) suggesting that diagnosis of a clinically significant event took place on or
following the index event. Of note, certain Charlson categories were observed at
considerably higher rates in the follow up period only as compared to pre-index only,
e.g., COPD (4.7% pre-index only, 11.05% in follow-up only) and MI (0.59% preindex only, 1.57% in follow-up only) (data not shown). This trend suggests that
diagnosis of COPD or MI may lead practitioners to subsequently code for tobacco
dependence.
We found that patients with pre-index diagnosis of HIV had the highest rates of
SCM prescription while those with MI had the lowest. Individuals who are HIVpositive are more likely to smoke than the general population and HIV-positive
smokers have higher mortality rates and greater likelihood of infectious comorbidities
than HIV-positive non-smokers.22-27 In addition, daily tobacco may possibly attenuate
the immune and virological response to antiretroviral therapies.28 The finding of high
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rates of SCM use in patients with HIV-AIDS diagnosis in the present study reflects
clinician recognition of particular risk of tobacco dependence in these patients. In
contrast, the low rate of SCM prescribing in patients with MI diagnosis at baseline
was surprising as stopping smoking after MI is one of the most effective actions for
secondary prevention of CVD 29. Others have described tobacco use as the forgotten
cardiac risk factor, its treatment possibly receiving less attention than treatment of
hypertension, hyperlipidemia or diabetes.29 30
Our finding that a pre-index cancer diagnosis was associated with lower
likelihood of receiving SCM is worth discussion. The USPHS reports cancer as a
comorbidity in which SCM has been demonstrated as beneficial.3 Health benefits can
results from smoking cessation after a cancer diagnosis at any stage or prognosis and
National Comprehensive Cancer Network (NCCN) recommends that treatment plans
for smokers with cancer include pharmacotherapy as an option for intervention.31 Of
note, results of a survey by Warren et al report that physicians caring for lung cancer
patients believe that current smoking affects outcomes and that tobacco cessation is a
necessary part of clinical care, but few provide assistance to their patients as a routine
part of cancer care.32 Our results underscore the possible opportunity to study use and
timing of SCM prescribing in patients with cancer.
Stratification of patients prescribed SCM by physician type (those diagnosing
their tobacco dependence) revealed some interesting findings. The most common
diagnosing specialty was the category of general medicine (56.95%) and more patients
(14.35%) were treated with SCM who were diagnosed as tobacco dependent by a
general medicine practitioner than any other specialty. The lowest proportions of
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SCM treated patients were those whose diagnosis was made by a hospital related
physician (4.92%) or a therapeutic specialist (7.06%), though these were the second
and third most common diagnosing specialty (35.23% and 9.83%, respectively).
Encounters with hospital related practitioners has been identified as a teachable
moment to motivate individuals to risk reducing behaviors such as smoking
cessation33
Hospitalization is an opportunity for patients to attempt to quit tobacco as they are
likely to be in a smoke-free environment and may be particularly motivated by an
illness caused or exacerbated by tobacco use (Fiore 2008). Patients can be encouraged
to remain smoke free after discharge and begin treatment in the hospital. In a metaanalysis of randomized controlled trials of smokers hospitalized for a CVD diagnosis,
a smoking cessation intervention begun in the hospital and sustained for at least 1
month post-discharge, increased cessation rates by 42% (RR: 1.42, 95% CI: 1.29–
1.56) 6–12 months post-discharge and starting NRT in hospital increased quit rates
over counselling alone.34 Furthermore, in a trial of smokers hospitalized with MI,
compared to usual care, intensive intervention with counseling and pharmacotherapy
increased cessation rates and reduced all-cause mortality and hospital readmission.35
Furthermore, compared to diagnosis made by general medicine practitioner,
patients diagnosed by any other practitioner type had lower odds of SCM prescription.
Rates of treatment with SCM by physician type is not widely described, however
Rigotti, et al state that cardiologists have a special opportunity to promote cessation
since a smoker receiving a diagnosis of CHD may see the health risks of smoking
suddenly personally salient and be motivated to reduce future risk. 29 As described
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above, the NCCN recommends the same importance of fostering smoking cessation by
oncologists. It should be noted that a patient may have received a diagnosis by
multiple specialties on the same date, indicating multiple interactions with the health
care system on the same date and possibly suggestive of the occurrence of an event.
This study utilized data from medical and pharmacy claims which are collected
for billing and reimbursement purposes and which have inherent limitations. We used
ICD-9-CM and tobacco cessation counseling specific CPT and HCPCS codes to
identify smokers, excluding those with these and SCM codes in the 12 months preindex. While this method may under-estimate the number of smokers and SCM treated
patients, use of ICD-9-CM codes to identify smokers has been validated previously
and the utility of administrative claims to describe SCM demonstrated.36,9,10 The use
of prescription claims exclusively in the current study may have missed the use of
over the counter (OTC) products, but in an US insured population, over the counter
SCM may be covered under the pharmacy benefit. It is difficult to estimate the extent
to which OTC NRT is used, but results of an international survey of smokers using
SCM in a quit attempt indicated that 68.3% of subjects self-report OTC NRT use. Of
note, those who obtained OTC NRT appeared more likely to discontinue in the first
week of use than those receiving NRT by prescription (23% vs. 13.4%, respectively.37
As mentioned above, description of SCM coverage by Medicaid is often publicly
available, but coverage by private health plans is not as widely reported and benefit
designs can change frequently. However, a survey of Tennessee health plans yields
some insight where researchers found wide variation in coverage of prescription and
over-the counter medications with bupropion covered most often, followed by
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varenicline, NRT patches and gum, then other forms of NRT. Given that the
Affordable Care Act requires all new private health insurance plans to cover services
recommended by the US Preventative Services Task Force including tobacco
cessation treatments, future study using administrative data may yield different results.
Moreover, evolution of reimbursement to incentivize physicians to intervene to aid
tobacco cessation may lead to increased use of coding over time. Although data used
in this study were collected from all U.S. census regions, due to geographic biases,
any unprojected geographic information may not be representative of the true
distribution. Finally, the small number of patients in some subgroups evaluated
precludes comparisons by statistical analysis and thus, results are descriptive in nature.
It is important to note that though patients were identified as smokers through
diagnosis or procedure codes, this provides no insight into readiness to quit which is
an important component of cessation attempts.3
Despite these limitations, this study adds important information regarding the
epidemiology of the use of SCM in the U.S. Specifically, despite guidance describing
pharmacotherapy as an option to aid most patients in quitting, approximately 11% of
newly diagnosed tobacco dependent patients received treatment within a year of
diagnosis, and the youngest and oldest patients were less likely to receive SCM than
those at middle age. Additionally, the lowest proportions of SCM treated patients were
those whose tobacco dependence diagnosis was made by a hospital related physician.
Perhaps the most concerning finding was that patients with possibly tobacco related
co-morbidities are less likely to receive treatment than those without. These findings
suggest opportunity for more focused research with regard to use and timing of SCM
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in these at risk populations. In addition to the findings regarding the epidemiology of
SCM, this study suggests that diagnosis or procedure for tobacco dependence took
place co-incident with occurrence of another co-morbidity and also suggests further
study in the areas of systematic and early documentation of tobacco dependence which
may facilitate earlier intervention.
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Table 1.1. Rate of SCM Prescribing by Demographic Characteristics among
Patients Diagnosed with Tobacco Dependence, LifeLink™ Health Plan Claims
Database,
(July 2010-June 2011)
Total
(N = 15,000)
Age at index,
years, mean,
46.08 (± 14.46)
(SD)
Age Category, No. (%)

No Rx for SCM in 1
yr follow up
(n=13,379)
46.27 (14.67)

Rx for SCM in 1
yr follow up
(n=1,621)
44.56 (12.52)

p-value
<0.0001

18-24

1,598 (10.65)

1491 (93.30)

108 (6.76)

25-34

1,984 (13.23)

1700(85.69)

284 (14.31)

35-44

2,590 (17.27)

2233 (86.22)

357 (13.78)

45-54

3,965 (26.43)

3475 (87.64)

490 (12.36)

55-64

3,533 (23.55)

3219 (91.11)

314 (8.89)

65-75

1,283 (8.55)

1217 (94.85)

65 (5.07)

8,174
(54.49)
6,826 (45.51)

7248(88.67)

926 ( 11.33)

6131 (89.82)

695 (10.18)

<0.0001

Gender, No. (%)
Female
Male

0.0243

Patient Geographic Region, No. (%)
East

1,577 (10.51)

1403 (88.97)

174 (11.03)

Midwest

10,590 (70.60)

9254 (87.38)

1337 (12.62)

South

76 (0.51)

≤75 (≤98.68)

≤5 (≤6.58)

West

2,757 (18.38)

2647 (96.01)

110 (3.99)

459 (87.10)

68 (12.90)

<0.0001

Payer Type/Benefit Design, No. (%)
Consumer
Directed
HMO

527 (3.51)
10,342 (68.95)

0.1145
9212 (89.07)

1130 (10.93)
0.4818

208 (1.39)

188 (90.38)

20 (9.62)

0.5773

POS

6,383 (42.55)

5589 (87.56)

794 (12.44)

<0.0001

PPO

1,133 (7.55)

1038 (91.62)

95 (8.38)

0.0063

10494 (88.26)

1396 (11.74)

<0.0001

1796 (87.44)

258 (12.56)

0.0058

416 (92.04)

36 (7.96)

0.0481

392 (94.92)

21 (5.08)

0.0001

Indemnity

Commercial
Medicaid
Medicare
Supplemental
Medicare
Advantage

11,890 (79.27)
2054 (13.69)
452 (3.01)
413 (2.75)

1702 (92.90)
130 (7.10)
<0.0001
1832 (12.21)
Self-insured
Rx=dispensed prescription, HMO=health maintenance organization, POS=place of service,
PPO=preferred provider organization, SD=standard deviation, yr-year, No. = number
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Table 1.2. Rate of SCM use by Clinical Characteristics in Patients Diagnosed
with Tobacco Dependence, LifeLink™ Health Plan Claims Database (July 2010June 2011)
No Rx for SCM
in 1 yr follow up
(n=13,379)
9388 (88.48)

Rx for SCM in 1
yr follow up
(n=1,621)
1222 (11.52)

<0.0001

1698 (89.75)

194 (10.25)

0.4072

1300 (8.67)

1189 (91.46)

111 (8.54)

0.0058

Cancer

640 (4.27)

600 (93.75)

40 (6.25)

<0.0001

Mild liver disease
Peripheral Vascular
Disease (PVD)
Cerebrovascular
Disease (CVD)
Diabetes sequelae

442 (2.95)

405 (91.63)

37 (8.37)

0.0941

368 (90.86)

37 (9.14)

0.2722

313 (90.46)

33 (9.54)

0.4417

272 (1.81)

254 (93.38)

18 (6.62)

0.0247

RA
Congestive Heart
Failure (CHF)
Myocardial
Infarction(MI)
Renal disease

239 (1.59)

219 (91.63)

20 (8.37)

ns

213 (94.25)

13 (5.75)

0.0137

171 (96.07)

7 (3.93)

0.0030

176 (1.17)

164 (93.18)

12 (6.82)

0.0865

Metastatic cancer

70 (0.47)

70 (100)

<=5 (≤7.14)

<0.01

Paralysis

51 (0.34)

46-50 (≤98.03)

≤5 (≤9.80)

ns

Total (N=15,000)
No CCI comorbidity (CCI=0)
Chronic Obstructive
Pulmonary Disease
(COPD)
Diabetes

10610 (70.73)

p-value

1892 (12.61)

405 (2.70)
346 (2.31)

226 (1.51)
178 (1.19)

76-80 (≤98.77)
≤5 (≤6.17)
ns
Ulcer
81 (0.54)
Moderate to severe
26-30 (≤96.77)
≤5 (≤16.13)
ns
31 (0.21)
liver disease
25 (78.13)
7 (21.88)
0.0435
HIV/AIDS
32 (0.21)
CCI, mean, (SD) in
0.540 (± 1.184)
12 months pre-index
0.5571 (1.210)
0.402 (0.936)
<0.0001
CCI, mean, (SD)
during 1 year follow
0.774 (± 1.480)
0.780 (1.488)
0.726 (1.407)
0.1645
up period
Rx=dispensed prescription, CCI=Charlson Co-morbidity Index, HIV/AIDS=Human immunodeficiency
Virus/Acquired Immune Deficiency Syndrome
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Table 1.3. SCM Prescribing Rate by Diagnosing Practitioner Type, in Patients
Diagnosed with Tobacco Dependence, LifeLink™ Health Plan Claims Database,
July 2010-June 2011*

General Medicine
(GP/FP, Internal
Medicine, NP,
Ob/Gyn, Osteopath,
PA)
Hospital related
(surgical, ER,
hospital?,
anesthesia,
Orthopedics)
Specialist (e.g.,
cardiologist,
pulm,onco, endo,
ENT,
gastro,ID,allergist,
nephro, neuro,
ophthl, optom,phys
med, podiatrist,
psychi,rheum,urol)
Other (DME_HH,
PT, RN,
SOC_WORK,
MHSA_FAC)
Pediatrics
(pediatrics, neonatal)

No Rx for SCM
in 1 yr follow up
(n=13,379)

Rx for SCM in 1
yr follow up
(n=1,621)

p-value

Total (N=15,000)

8543 (56.95)

7317 (85.65)

1226 (14.35)

<0.0001

5285 (35.23)

5025 (95.08)

260 (4.92)

<0.0001

1370 (92.94)

104 (7.06)

<0.0001

283 (88.99)

35 (11.01)

0.9077

85 (89.47)

10 (10.53)

0.9296

1474 (9.83)

318 (2.12)
95 (0.63)

*Multiple specialties diagnosing the patient on the same date possible
GP=general practice, FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology,
PA=physician’s assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine,
ENT=ear, nose & throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist,
neuro=neurologist, ophth=ophthalmologist, optom=optometrist, phys med= physical medicine,
pscych=psychiatrist, rheum=rheumatologist, urol=urologist, DM_HH=durable medical
equipment/home health, PT=physical therapist, RN=registered nurse, SOC_WORK=social worker,
MHSA_FAC=mental health/substance abuse facility
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Table 1.4. Summary of Logistic Regression Analysis of Predictors of Treatment
with SCM in Tobacco Dependent Patients: Odds Ratios and 95% Confidence
Intervals
Variable
Age <18 (ref=45-54)
Age 18-24 (ref=45-54)
Age 25-34 (ref=45-54)
Age 35-44 (ref=45-54)
Age 55-64 (ref=45-54)
Age 56-75 (ref=45-54)
Diagnosis by Pediatrician
(ref=general medicine)
Diagnosis by Specialist
(ref=general medicine)
Diagnosis by Hospital related
Practitioner
(ref=general medicine)
Diagnosis by Other (nonphysician)
(ref=general medicine)
Pre-indexMI diagnosis
Pre-index Cancer Diagnosis

Odds Ratio

95% Wald CI

0.353
0.539
1.135
1.138
1.066
0.622
0.880

0.084-1.479
0.429-0.676
0.962-1.338
0.978-1.325
0.782-1.452
0.533-0.725
0.447-1.735

0.600

0.478-0.754

0.332

0.285-0.386

0.840

0.543-1.302

0.467
0.701

0.217-1.007
0.503-0.978

Pre-index HIV-AIDS
2.238
0.880-5.691
Hosmer and Lemeshow Test p=0.7528
ref=reference
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Figure 1.1. Sample Selection.- Tobacco Dependent Patients and Treatment with
SCM, LifeLink™ Health Plan Claims Database (July 2010-June 2011)
LifeLink™ Health Plan Claims Database enrolled patients: N=18,400,000 as of August 2012*
Continuously enrolled patients January 2009 – June 2012
Patients aged 16-76 identified as having any tobacco related diagnoses or procedure, SCM or smoking
related cancers
n = 117,695
Patients identified as having any tobacco related diagnoses or procedures or smoking related cancers
(Patient count without smoking cessation treatment)
n=80,486
Patients enrolled January 2009 to June 2012 with a diagnosis or procedure indicating tobacco
dependence (Patient count without smoking related cancer)
n=77,736
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010
and June 2011 (index)
n=18,619
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 and June
2011 with claims activity throughout the study period (January 2009 – June 2012)
n=16,417
Patients with no claims for SCM in the 18 month period pre-index
n=15,000
No Rx claim for SCM in 12 months post
index
n = 13,379

Rx claim for SCM in 12 months post-index
n = 1,621

*Closest estimate for continuously enrolled patients during the study period is 18.4MM patients as of
August 2012. Enrollment is subject to change quarterly as updates are received from contributing
health plans. Largest changes are typically seen at year beginning when patients may leave a health
plan and join another. The data used for this study has been merged into a new larger database called
Pharmetrics Plus which includes a larger number of contributing health plans. The database that
includes the data used for this study is archived and would require data restoration to determine exact
count.
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Figure 1.2. SCM Prescribed in 1 Year Following Diagnosis, LifeLink™ Health
Plan Claims Database (July 2010-June 2011) (n=1647)
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Background

Duration of use of smoking cessation medications (SCM) has been associated
with treatment success in clinical trials.1-3 However, literature reports of “real world”
studies evaluating SCM treatment duration and quit outcome in clinical practice are
few. One United States (US) based population survey examined the association of
duration of nicotine replacement therapy (NRT) use and found no/ association with
quit rates, though the population surveyed was specific to Massachusetts, which
provides free NRT to interested persons.4,5 In contrast, results of a retrospective study
employing Canadian survey data which examined the association between duration of
NRT use and smoking cessation indicated that NRT use for less than 4 weeks was
associated with reduced likelihood of cessation, whereas use for longer periods was
associated with a higher likelihood of cessation.6 Of note, the aforementioned studies
are limited to examination of NRT which is available over the counter (OTC) in the
US and literature reports of US population-based studies examining the association of
duration of prescription medication use with smoking cessation are scant. However,
one study employed the Tobacco Use Supplement to the US Current Population
Survey and results indicated that treatment with SCM for at least 5 weeks was
associated with higher likelihood of successful smoking cessation.7 No studies
employing administrative claims data to assess duration of therapy (persistence) have
been published.
Another important consideration in assessing SCM use is recognition that tobacco
dependence is a chronic disease that often requires repeated intervention with the
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average smoker making 6 to 9 lifetime quit attempts.8 Thus, patient relapse to tobacco
use following a period of abstinence achieved with use of SCM is not unexpected.
Treatment guidelines encourage clinicians to prescribe/recommend medications plus
counseling for each quit attempt and research suggests that smokers are willing to
make repeated pharmacotherapy assisted quit attempts.8,9 However, few reports exist
in the literature that describe repeat therapy with SCM in clinical practice and none
were found that use administrative data sources.
In a single center retrospective cohort study of repeat treatment for smoking, Han,
et al found that patients who relapsed to smoking and returned for repeat treatment
exhibited signs of higher nicotine dependence and were more likely to have a history
of treatment for mental health and other behavioral problems than patients who only
attended for one treatment episode.10 Moreover, a randomized controlled trial (RCT)
evaluating intensive disease management strategies for smokers over time found that
smokers are willing to make repeated quit attempts using SCM, leading to
progressively greater smoking abstinence.9 Study of repeat treatment in a large
national population could identify patient or provider characteristics associated with
repeat treatment and inform specific approaches to management in patient subgroups.
The objectives of this study were to describe treatment persistence in newly diagnosed
tobacco dependent patients prescribed SCM in the 1 year following diagnosis, repeat
treatment with SCM and patient and prescriber characteristics associated with
premature discontinuation and repeat therapy.
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Methods
Design: This study employed a retrospective cohort design using de-identified
data from the LifeLink™ Health Plan Claims Database (formerly known as
Pharmetrics) which is comprised of commercial health plan information obtained from
managed care plans throughout the US. It is fully adjudicated medical and
pharmaceutical claims for over 68 million unique patients from over 102 health plans
across the U.S. (approximately 16 million covered lives per year). The database
includes both inpatient and outpatient diagnoses (In International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] format) and procedures
(in Current Procedure Terminology [CPT-4] codes and Healthcare Common
Procedure Coding System [HCPCS] formats) as well as both retail and mail order
prescription records. Available data on prescription records include the National Drug
Code (NDC) as well as the quantity of the medication dispensed. Charge, allowed and
paid amounts are available for all services rendered, as well as dates of service for all
claims. Additional data elements include demographic variables (age, gender,
geographic region), product type (e.g., HMO, PPO), payer type (e.g., commercial,
self-pay), provider specialty, and start and stop dates of health-plan enrollment.
Sample Selection: The sample consisted of patients aged 16-76 newly identified
as tobacco dependent through presence of a diagnosis code for tobacco use disorder
and/or CPT code for tobacco cessation counseling, advice or treatment (Appendix)
during the period July 2010 to June 2011 (index). Patients with ICD-9, CPT codes, or
prescriptions related to tobacco dependence or treatment in the lookback period
January 2009 through June 2010 were excluded. Charlson Comorbidity Index (CCI)
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scores for each patient were calculated using the algorithm develop by Quan, et al.,
through identification of ICD-9 codes related to 17 co-morbidity categories in the
12 month period prior to (pre-index) and 12 month period following the index date
(including the index date). Weights specific to each co-morbidity category were
assigned and the CCI score calculated; higher CCI scores indicate greater comorbidity.11
Statistical Analysis: Descriptive statistics were used to describe demographic and
clinical characteristics and frequency of prescription of SCM defined as 1 or more
claim for varenicline, bupropion SR or NRT during the 1 year period following
tobacco dependence diagnosis or CPT code or procedure. Demographic
characteristics included patient age at index, gender, geographic region of residence
and insurance related factors such as payer type and insurance product. Clinical
characteristics included baseline 12 month pre-index CCI score and CCI categories.
Provider characteristics included the practitioner type associated with diagnosis of or
counseling/advice for tobacco dependence.
Two dichotomous response variables were defined: Premature discontinuation
and repeat therapy. Premature discontinuation or non-persistence was defined as
duration of therapy less than 12 weeks (84 days) based on recommended duration of
therapy as described in FDA approved product information for varenicline and
bupropion SR and, due to multiple available formulations, expert recommendation for
NRT.12-14 Data fields employed to calculate duration of therapy included the patient
identification number, product name, prescription fill date and days supply. Time to
discontinuation in days was measured using a refill grace period equal to one-half the
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days supplied of the previous prescription. Repeat treatment was defined based on
criteria used by Han, et al.10 Patients were identified as having repeat therapy if a span
of ≥ 26 week was observed between any 2 consecutive treatment episodes in the 1
year following initiation of SCM. Bivariate analyses including t-tests for continuous
variables and chi-square tests or Fisher’s Exact test for categorical variables were used
to analyze differences in patient and provider characteristics.
Assessment of factors associated with premature discontinuation or repeat therapy
was performed by conducting a series of univariate logistic regression equations. To
qualify for multivariate logistic regression, variables had to be associated with SCM
prescription in the univariate analyses (p<0.2) or be otherwise clinically important.
Two multivariate logistic regression models were constructed; the first assessed
relationships between the independent variables (IVs) of patient and provider
characteristics and the dependent variable (DV) of premature discontinuation of SCM
therapy and the second assessed relationships between the IVs of patient and provider
characteristics and the dependent variable (DV) of repeat SCM therapy as defined
using Han’s criteria. For modeling the DV of repeat therapy, infrequently occurring
(≤5 patients) independent variable categories were combined. Each model was created
using a backward elimination process and the likelihood ratio test and AIC used to
assess the model at each step, removing least statistically significant covariates with
each iteration and evaluating differences between full and reduced models for
statistical significance. In advance of model inclusion, parametric form of any
continuous independent variables and multicollinearity among independent variables
were assessed. Multicollinearity was assessed by regressing independent variables

32

against the independent variable of patient age at index. Main effects and two factor
interactions of independent variables found significant in the models were assessed.
The Hosmer-Lemeshow test was used to assess goodness of fit of the final models.
The measure of effect is presented as an odds ratio with corresponding 95%
confidence intervals. All analyses were conducted using SAS® Version 9.4 (SAS
Institute, Cary, NC) with statistical significance defined as p <0.05. Analyses were
performed using a 2-tailed alpha of 0.05 and 95% confidence intervals calculated.

Results
Cohort
In total, 1621 of 15,000 (10.81%) newly diagnosed tobacco dependent patients
initiated therapy with SCM in the 1 year following diagnosis (Figure 1). Of treated
patients, mean (SD) age was 44.56 (12.52) years, 57.13% were female and most
(82.11%) resided in the Midwest. Mean (SD) pre-index Charlson Comorbidity index
score (CCI) was 0.402 (0.935) and most (86.12%) had commercial insurance and an
HMO insurance product (69.77%). Most (75.63%) were diagnosed by a general
medicine practitioner (Table 1). Smoking cessation medication prescriptions in the 1
year post-index included 71 (4.38%) bupropion SR, 450 (27.76%) NRT and 1126
(69.46%) varenicline (Figure 2).
Persistence
Mean (SD) duration of therapy in all treated patients was 36.35 (25.74) days.
Premature discontinuation, defined as duration of therapy <84 days, was observed in
1506 (92.91%) of patients. Mean (SD) age of patients who prematurely discontinued
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SCM was 44.29 (12.55) years and mean (SD) pre-index baseline CCI was 0.4070
(0.9497). Differences were observed by age group with patients >50 years being less
likely to discontinue prematurely than their younger counterparts (p=0.0040), and also
by region (p=0.0052) with the highest rates in patients from the East (94.25%) and
lowest in patients from the South (≤5) and West (84.55%) Premature discontinuation
did not differ according to CCI score category (p=0.4778) with the highest rate in
patients with CCI=1 (94.64%) and lowest in CCI ≥2 (92.03%) (Tables 1, 2). Overall,
premature discontinuation was similar (p=0.0705) by payer type and insurance
product with highest and lowest rates in patients with Medicaid (94.96%) and
Medicare Supplemental (83.33%) and POS (93.71%) and PPO (88.42%), respectively.
Premature discontinuation was not different (p=0.7875) by diagnosing provider type
with highest reportable (count >5) rate in patients diagnosed by hospital related
practitioners (93.85%) (Table 3). No difference in premature discontinuation rate was
observed between in patients who ultimately repeated therapy and those who did not
(p=0.8291) (Table 3). Differences were observed in rates of premature
discontinuation between SCM with the highest rate in nicotine policrilex (97.47%) and
lowest in bupropion SR (80.28%) (p<0.001) (Table 1).
Multivariate logistic regression analysis revealed that patients in age groups 5164 years had slightly lower likelihood of premature discontinuation compared to
patients age 41-50 (OR 0.584, 95% CI 0.354-0.962), as did patients residing in the
South or West compared to those residing in the Midwest (OR 0.325, 95% CI 0.1730.610) . Patients in Medicaid had higher likelihood of premature discontinuation
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compared to those with commercial insurance (OR 2.898, 95% CI 1.179-7.122) (Table
5).
Repeat Therapy
Of the 1621 treated patients, 86 (5.3%) were identified as having repeat therapy
and mean (SD) age in this group was 44.3 (12.88) years and pre-index baseline mean
(SD) CCI score in patients who repeated therapy was 0.4186 (1.034). Repeat
treatment rate was similar in females and males (5.62% vs 4.89%, p=0.5201). Patients
in CCI score category ≥2 had the lowest rate of repeat therapy (4.35%, p=0.8379).
Rates of repeat therapy by insurance product (p=0.3084), payer type (p=0.7956) and
diagnosing practitioner type (p=0.2773) were similar with the lowest rates in patients
with consumer directed insurance (≤5) and indemnity (≤5) and highest in patients with
HMO (6.02%). Repeat treatment rate by age group was similar (p=0.4242) and lowest
in the youngest and oldest age groups of 17-19 (≤5) and 65-75 (≤5) with patients 2049 years having the highest repeat therapy rate (5.95%). Similarly, no difference was
observed in repeat treatment by region with lowest counts in patients residing in the
South and West (≤5) and highest in the East (5.75%). No difference in premature
discontinuation rates (5.39% vs. 94.62%, p=0.6346) or mean (SD) duration of initial
therapy (34.53 [20.14] days vs. 36.43 [26.02] days, p=0.5071) was observed in
patients who repeated therapy compared to those who did not. Repeat therapy rates
did not differ among products (p=0.919) (Table 5). Multivariate regression analysis
revealed no variables that were associated with repeat therapy (Table 7).
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Discussion
Population assessments of persistence with SCM are few and are derived largely
from survey data with some focusing exclusively on NRT.4,6,7,15 Though study design,
data source and populations differ, our findings related to premature discontinuation
can be compared most closely to a study of international survey data that used a
threshold to define premature discontinuation. The authors defined premature
discontinuation as self-report of <8 weeks of treatment, whether OTC or prescription,
and found that most patients studied (69%) discontinued therapy prematurely.15 These
authors concluded that older age was a significant predictor of completing >8 weeks
of therapy (OR 1.02, 95% CI 1.01-1.03) and that completion of a full 8 weeks of SCM
was more likely among prescription SCM users (OR 1.82, 95% CI 1.29 – 2.57) and
females (OR 1.16, 95% CI 0.88-1.53), though the confidence interval for the latter
included 1.0. Of prescription SCM users in that study, duration of therapy 8 weeks or
more was reported by 40.4%.
In the present study using administrative claims data which are exclusive to
therapies dispensed by prescription, results indicate that >90% of newly diagnosed
tobacco dependent patients discontinue therapy before 12 weeks. We found that 100%
of patients <20 years old discontinued prematurely and those between 51 and 64 years
were slightly less likely to premature discontinuation compared to those aged 41-50
(OR 0.584, 95% CI 0.354 – 0.962). We found no difference (p=0.2657) in the rate of
premature discontinuation between males and females and no association of gender
with premature discontinuation. Mean duration of therapy in the current study was
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approximately 36 days and only 15% had duration of therapy >8 weeks (Data not
shown).
We did observe regional differences (p= 0.0052) in premature discontinuation
rate with the lowest rate in the West (84.55%) but comparisons were hampered by low
counts of treated patients from the South. Residence in the West or South was
associated with slightly lower likelihood of premature discontinuation (OR 0.354,
95% CI 0.354-0.962) compared to the Midwest, however these results are likely
influenced by the lower premature discontinuation rate in the West because of low
SCM utilization in the South (≤5 patients treated; ≤5 prematurely discontinuing).
Literature reporting SCM persistence in different US regions has not been found.
Patients with Medicaid had higher likelihood of premature discontinuation compared
to those with commercial insurance (OR 2.898, 95% CI 1.179-7.122), though the
confidence interval is wide. Similar to aforementioned lack of information regarding
reports of SCM persistence rates by region, reports of persistence with SCM by payer
type have not been found.
Differences were observed in rates of premature discontinuation between SCM
with highest rate in nicotine polacrilex (97.47%) and lowest in bupropion SR
(80.28%) (p<0.001). As mentioned previously, population based studies reporting
SCM persistence is scant but, in a randomized controlled trial (RCT) comparing the
efficacy and safety of varenicline and bupropion SR, discontinuation rates in those
receiving treatment were similar with 24.12% varenicline and 29.14% of bupropion
SR subjects discontinuing therapy; 10.5% due to adverse events in the varenicline
group, and 12.6% in the bupropion SR group.16 Similar results were observed in a
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parallel RCT of varenicline and bupropion.17 Differences in mechanisms of action of
these two drugs could yield different responses, such as reduction in craving, nicotine
withdrawal symptoms and rewarding effects of smoking.18

Bupropion SR is

indicated in both depression and as a smoking deterrent so use in patients with mental
health diagnoses was possible.
Of note, in their survey of smokers or recent ex-smokers having used SCM in a
quit attempt in the previous year, Balmford, et al15 found that the most commonly
reported reason for discontinuation was relapse/medication didn’t work (41.6%).
Interestingly, this reason was much less commonly reported among users of
prescription only medication; discontinuation was described more frequently as related
to side effects. The authors found no difference in proportions of patients completing
treatment courses of oral NRT and the patch.15 Of note, a considerable portion of
SCM users (17%) in this study believed they no longer needed to use medication, and
two thirds of those who believed the medication had worked achieved 6 months
continuous abstinence.11 The authors note that people may be able to judge the
appropriate time to discontinue medication and suggest that a trial of participant point
of discontinuation may be worthwhile.
Tobacco dependence is a chronic disease that often requires repeated intervention
and multiple attempts to quit but few reports exist that describe repeat therapy with
SCM in actual practice. In a single center retrospective cohort study, Han, et al
studied the characteristics of patients who relapsed to smoking and returned to the
clinic for repeat treatment.10 The authors defined a repeat patient as one who attended
clinic for two or more treatment episodes during the study period with each episode
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being separated by at least 26 weeks. The study results indicated that 14.4% of
patients repeated treatment which was more common between ages 25 and 64 than
younger or older age groups (p=0.017) and in patients who had private insurance
(56.6%, p=0.010). In the current study, repeat treatment was observed in ~5% of
newly diagnosed tobacco dependent patients initiating SCM and demographic and
clinical characteristics, insurance related factors, and diagnosing practitioner types in
those repeating treatment were similar to those who did not. It is possible that those
patients for whom providers use diagnosis codes for tobacco cessation or counsel for
tobacco cessation are those with high levels of tobacco dependence and these patients
have been found to have greater rates of smoking relapse following a quit attempt.19
While not a study of routine practice, results of a randomized controlled trial of
community based patients participating in a longitudinal intensive smoking cessation
management program indicated that, by study end, 23%, 33% , 23%, 12% and 9%
requested a total of 0,1,2,3 or 4 cycles of pharmacotherapy, respectively.9
This study utilized data from medical and pharmacy claims which are collected
for billing and reimbursement purposes and which have inherent limitations. Data
entry errors at sites of care cannot be detected or corrected in data analysis. We used
ICD-9-CM and tobacco cessation counseling specific CPT and HCPCS codes to
identify newly diagnosed smokers. This method may under-estimate the number of
smokers, however use of ICD-9-CM codes to identify smokers has been validated
previously.20 The use of prescription claims exclusively in the current study may have
missed the use of over the counter (OTC) products, but in an US insured population,
over the counter SCM may be covered under the pharmacy benefit. The small number
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of patients in some subgroups evaluated precludes comparisons by statistical analysis
and thus, results are descriptive in nature. It is important to note that though patients
were identified as smokers through diagnosis or procedure codes, this provides no
insight into readiness to quit which is an important component of cessation attempts.8
Also, as mentioned only prescription SCM could be captured and payment of a
prescription claim does not mean that a patient used the medication as prescribed and
does not represent those prescriptions that may have been written but not filled by the
patient. Thus, treatment rates may be underestimated in this sample.
Identification of SCM use or tobacco dependence diagnosis or procedure prior to
the lookback period was not possible, thus patients may have been misclassified as
newly diagnosed and/or newly treated with SCM. In addition we did not identify any
mental health comorbidities in which bupropion SR could have been used to treat both
conditions.
Recommended duration of therapy for specific SCM can vary based on level of
tobacco dependence and clinical information such as level of tobacco dependence is
not ascertainable in claims data. The threshold of 12 weeks was chosen as it is the
minimum recommendation for varenicline, upper limit of recommendation for
bupropion SR and within recommendations for NRT.12-14 Premature discontinuation
of SCM does not mean that patients did not quit. Aforementioned population studies
found that patients successfully quit using shorter than recommended durations of
therapy, however cessation rates have been found to be highest among those who use
prescription medication for ≥5 weeks.6,7
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Future research using administrative claims data should focus on different
persistence thresholds and include longer study periods. Additionally, long term
prospective study of patients using SCM would facilitate study of persistence and
repeat therapy. Important clinical information could be gained by linking
administrative claims to electronic medical record data in a HIPAA compliant fashion.
Despite stated limitations, this study adds useful information regarding
persistence and repeat use of prescription SCM in a US national population.
Specifically, mean persistence with SCM was approximately 36 days and >90% of
patients discontinued SCM before 12 weeks of therapy; shorter than
recommendations. Patients under 50 years and 65 or older were more likely to
discontinue prematurely than patients 50-58 years old. Few patients (5%) repeated
therapy and, in this study with small sample size, no patient or provider characteristics
were associated with repeat therapy.
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Table 2.1. Demographic Characteristics of Tobacco Dependent Patients with
Premature SCM Discontinuation , LifeLink™ Health Plan Claims Database
(July 2010-June 2011)

Age at index, years, mean,
(SD)
Age Category, No. (%)
17-19

Total
(N = 1621)
44.56
(12.52)

Premature
Discontinuation
= no (n=115)

Premature
Discontinuation =
yes (n=1506)

48.15 (11.59)

44.29 (12.55)

0

30 (100)

52 (45.22)

906 (94.57)

45 (39.13)

374 (89.26)

59-64

30 (1.85)
958
(59.06)
419
(25.83)
150 (9.25)

12 (10.43)

138 (92.0)

65-75

65 (4.01)

6 (5.22)

59 (90.77)

60 (6.47)

866 (93.53)

55 (7.91)

640 (92.09)

10 (5.75)

164 (94.25)

88 (6.58)

1248 (93.41)

0

≤5 (≤100)

20-49
50-58 (reference)

p-value
0.0014

0.0040

Gender, No. (%)
Female
Male

926
(57.13)
695
(42.75)

0.2657

Region, No. (%)

South

174
(10.73)
1336
(82.11)
≤5 (≤0.31)

West (reference)

110 (6.79)

17 (15.45)

93 (84.55)

68 (4.19)

≤5 (≤7.35)

63 (93.65)

1131
(69.77)

81 (7.16)

1049 (92.84)

≤5 (≤25.0)

18 (≤95.0)

50 (6.30)

745 (93.70)

11 (11.58)

84 (88.42)

1396
(86.12)

103 (7.37)

1293 (92.62)

Payer Type Medicaid

258
(15.91)

13 (5.04)

245 (94.96)

Payer Type Medicare

57 (3.52)

9 (15.79)

48 (84.21)

Payer Type Self-insured

130 (8.02)

9 (6.92)

121 (93.08)

East
Midwest

<0.01

Insurance Related, No. (%)
Product Type Consumer
Directed
Product Type HMO
(reference)
Product Type Indemnity
Product Type POS
Product Type PPO
Payer Type Commercial
(reference)

20 (1.23)
795
(49.04)
95 (5.86)

1544
107 (6.93)
1438 (93.07)
Pharmacy Benefit
(95.25)
PPO = Preferred Provider Organization, POS = Point of Service
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ns

ns

0.2485

Table 2.2. Clinical Characteristics of Tobacco Dependent Patients with
Premature SCM Treatment Discontinuation, LifeLink™ Health Plan Claims
Database (July 2010-June 2011)*

Pre-index Charlson
Comorbidity Index
(CCI), mean, (SD)
Pre-index CCI 0, n
(%) (Reference)
Pre-index CCI 1, n
(%)
Pre-index CCI ≥2, n
(%)
Chronic Obstructive
Pulmonary Disease
(COPD)
Mean (SD) Duration
of Therapy (days)
Repeat Treatment
Bupropion SR
(n=71), No. (%)

Total
(N = 1621)

Premature
Discontinuation = no
(n=115)

0.402
(0.935)

Premature
Discontinuation = yes
(n=1506)

p-value

0.3391
(0.7241)

0.4070 (0.9497)

0.4532

1223 (75.44)

90 (7.36)

1133 (92.64)

261 (16.10)

14 (5.36)

247 (94.64)

138 (8.51)

11 (7.97)

127 (92.03)

194 (11.97)

17 (8.76)

177 (91.24)

0.3347

≤5 (≤5.81)

≤85 (≤98.84)

ns

36.35
(25.74)
86 (5.30)

14 (19.72)

Nicotine (n=371),
No. (%)

8 (2.16)

Nicotine Polacrilex
(n=79), No. (%)

≤5 (≤6.33)

Varenicline (n=1126),
No. (%)

0.4778

92 (8.17)

57 (80.28)

363 (97.84)

≤78 (≤98.73)

1034 (91.83)

*Results presented only for Charlson Comorbidities cell counts >5
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<0.0001

Table 2.3. Characteristics of Diagnosing Practitioners for Tobacco Dependent
Patients with Premature SCM Treatment Discontinuation, LifeLink™ Health
Plan Claims Database (July 2010-June 2011)

Total
(N = 1621)

Premature
Discontinuation = no
(n=115)

Premature
Discontinuation = yes
(n=1506)

p-value

General Medicine
(GP/FP, Internal Med,
1226 (75.63)
90 (7.34)
1136 (92.66)
NP, Ob/Gyn,
Osteopath, PA)
Hospital related
(surgical, ER,
260 (16.04)
16 (6.15)
244 (93.85)
hospital, anesthesia,
Ortho)
Specialist (e.g.,
ns
cardiologist,
pulmonol,oncol,
endocrine, ent,
gastro,ID,allergy,
104 (6.42)
9 (8.65)
95 (91.35)
nephrol, neurol,
ophthal, optom,phys
med, podiatry,
psychiatry,rheum,urol
)
Other (DME_HH, PT,
≤34 ≤97.14)
RN, SOC_WORK,
35 (2.16)
≤5 (≤14.28)
MHSA_FAC)
Pediatrics (pediatrics,
10 (0.62)
≤5 (≤50.0)
≤9 (≤90.0)
neonatal)
GP=general practice, FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology,
PA=physician’s assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine,
ENT=ear, nose & throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist,
neuro=neurologist, ophth=ophthalmologist, optom=optometrist, phys med= physical medicine,
pscych=psychiatrist, rheum=rheumatologist, urol=urologist, DM_HH=durable medical
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Table 2.4. Demographic Characteristics of SCM Treated Patients with Repeat
Therapy LifeLink™ Health Plan Claims Database (July 2010-June 2011)
Total
(N = 1621)
Age at index, years,
44.56 (12.52)
mean, (SD)
Age Category, No. (%)**

No repeat ≥26
weeks
(n=1535)
44.57 (12.51)

Repeat Rx ≥26
weeks (n=86)

p-value

44.30 (12.88)

0.8431

17-19

30 (1.85)

29 (96.67)

≤5 (≤16.67)

20-49

958 (59.06)

900 (94.04)

57 (5.95)

50-58 (reference)

419 (25.83)

403 (96.18)

16 (3.82)

59-64

150 (9.25)

143 (95.33)

7 (4.67)

65-75

65 (4.01)

≤64 (≤98.46)

≤5 (≤7.69)

926 (57.13)

874 (94.398

52 (5.62)

695 (42.75)

661 (95.11)

34 (4.89)

East

174 (10.73)

164 (94.25)

10 (5.75)

Midwest

1336 (82.11)

1262 (94.46)

74 (5.54)

≤5 (≤0.31)

≤5 (≤0.31)

0

108 (98.18)

≤5 (≤4.55)

68 (4.19)

≤67 (≤98.53)

≤5 (≤7.35)

1131 (69.77)

1062 (93.98)

68 (6.02)

20 (1.23)

≤19 (≤95.0)

≤5 ≤25)

752 (94.71)

42 (5.29)

≤94 (≤98.95)

≤5 (≤5.26)

1320 (94.56)

76 (5.44)

244 (94.57)

14 (5.43)

≤56 (≤98.25)

≤5 (≤8.77)

124 (95.38)

6 (4.62)

ns

Gender, No. (%)
Female
Male

0.5201

Region, No. (%)

South
West
(reference)***

110 (6.78)

ns

Insurance Related, No. (%)
Consumer Directed
Insurance Product
HMO
(reference)****
Indemnity
Insurance Product
POS
Insurance Product
PPO
Payer Type
Commercial
(reference)†
Payer Type
Medicaid
Payer Type
Medicare
Payer Type Selfinsured

795 (49.01)
95 (5.86)
1396 (86.12)
258 (15.91)
57 (3.53)
130 (8.02)

ns

ns

1459 (94.49)
85 (5.51)
0.1221
1544 (95.25)
Pharmacy Benefit
Repeat therapy defined if a span of ≥ 26 week was observed between any 2 consecutive treatment
episodes in the 1 year following initiation of SCM. PPO = Preferred Provider Organization, POS =
Point of Service
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Table 2.5. Rate of Repeat Therapy by Clinical Characteristics and Diagnosing
Practitioner Type in Patients Treated with SCM, LifeLink™ Health Plan Claims
Database (July 2010-June 2011)
Total
(N = 1621)
Pre-index Charlson Comorbidity
Index, mean, (SD)
Pre-index CCI 0, n (%)
(Reference)
Pre-index CCI 1, n (%)
Pre-index CCI ≥2, n (%)
Chronic obstructive pulmonary
disease

No repeat ≥26
weeks (n=1535)
0.4013 (0.9300)

Repeat Rx ≥26 weeks
(n=86)
0.4186 (1.034)

1157 (94.68)

65 (5.32)

261 (16.10)

246 (94.25)

15 (5.75)

138 (8.51)

132 (95.65)

6 (4.35)

183 (94.33)

11 (5.67)

1159 (94.54)

67 (5.46)

253 (97.31)

7 (2.69)

0.402 (0.935)
1223 (75.44)

194 (11.97)

pvalue
0.8675

0.8379
0.8091

Diagnosing Practitioner Type, No (%)
General Medicine (GP/FP,
Internal Med, NP, Ob/Gyn,
Osteopath, PA)
Hospital related (surgical, ER,
hospital, anesthesia, Ortho)
Specialist (e.g., cardiologist,
pulm,onc, endo, ent,
gastro,ID,allergist, nephro, neuro,
ophth, optom,phys med,
podiatrist, psych,rheum,urol)
Other (DME_HH, PT, RN,
SOC_WORK, MHSA_FAC)
Treatment Patterns
Premature discontinuation
(duration of therapy <84 days)
No. (%)
Duration of Therapy, mean (SD)

1226 (75.563)
260 (16.04)

ns
105 (6.42)

35 (2.16)

97 (93.27)

7 (6.73)

≤34 (≤97.14)

≤5 (≤14.29)

1425 (94.62)

81 (5.39)

1506 (92.91)

0.6346
36.43 (26.02)

34.53 (20.14)

Bupropion SR (n=71)

67 (94.37)

≤5 (≤98.59)

Nicotine (n=371)

355 (95.69)

16 (4.31)

Nicotine Policrilex (n=79)

76 (96.20)

≤5 (≤98.73)

1621 (100)

56 (4.97)
Varenicline (n=1126)
1071 (95.03)
*Results presented only for Charlson Comorbidities with cell counts >5; GP=general practice,
FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology, PA=physician’s
assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine, ENT=ear, nose
& throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist, neuro=neurologist,
ophth=ophthalmologist, optom=optometrist, phys med= physical medicine, pscych=psychiatrist,
rheum=rheumatologist, urol=urologist, DM_HH=durable medical equipment/home health, PT=physical
therapist, RN=registered nurse, SOC_WORK=social worker, MHSA_FAC=mental health/substance
abuse facility
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0.5071

ns

Table 2.6. Summary of Logistic Regression Analysis of Predictors of Premature
Discontinuation of SCM: Odds Ratios and 95% Confidence Intervals
Independent Variable
Age < 28 years
(ref=41-50 years)
Age 28-40
(ref=41-50 years)
Age 51-64 years
(ref=41-50)
Age 65-75 years
(ref=41-50 years)
East Region
(ref=Midwest)
South & West Regions
(ref=Midwest)

OR
3.164

95% Wald CI
0.939-10.662

0.946

0.535-1.676

0.584

0.354-0.962

0.796

0.292-2.171

1.478

0.726-3.012

0.325

0.173-0.610

Medicare and Self Insured
1.151
0.384-3.446
(ref=commercial)
Medicaid (ref=commercial)
2.898
1.179-7.122
Hosmer-Lemeshow Goodness of Fit Test
p=0.8672
ref=reference
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Table 2.7. Summary of Logistic Regression Analysis of Predictors of Repeat
SCM Therapy: Odds Ratios and 95% Confidence Intervals
Independent Variable

OR

95% Wald CI

Indemnity (ref=HMO)
POS (ref=HMO)
Diagnosis by non-physician or pediatrician or
specialist (ref=general medicine)
Diagnosis by hospital related practitioner
(ref=general medicine)
Hosmer-Lemeshow Goodness of Fit Test

0.329
0.623
1.176

0.045-2.424
0.355-1.093
0.550-2.513

0.464

0.198-1.087
p=0.9775

ref=reference; HMO=health maintenance organization, POS=Point of Service
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Figure 2.1. Sample Selection – Tobacco Dependent Patients Treated with SCM
and Repeat Therapy, LifeLink Health Plan Claims Database (July 2010-June
2011)
PharMetrics enrolled patients: N=18,400,000 as of August 2012*
Continuously enrolled patients January 2009 – June 2012
Patients aged 16-76 identified as having any tobacco related diagnoses or procedure, SCM or smoking
related cancers
n = 117,695
Patients identified as having any tobacco related diagnoses or procedures or smoking related cancers
(Patient count without smoking cessation treatment)
n=80,486
Patients enrolled January 2009 to June 2012 with a diagnosis or procedure indicating tobacco
dependence (Patient count without smoking related cancer)
n=77,736
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010
and June 2011 (index)
n=18,619
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 and June
2011 with claims activity throughout the study period (January 2009 – June 2012)
n=16,417
Patients with no claims for SCM in the 18 month period pre-index
n=15,000
Rx claim for SCM in 12 months post-index
n = 1,621
Repeat Rx ≥ 26 weeks
n=86
*Closest estimate for continuously enrolled in Pharmetrics during the study period is 18.4MM patients
as of August 2012. Enrollment is subject to change quarterly as updates are received from contributing
health plans. Largest changes are typically seen at year beginning when patients may leave a health
plan and join another. The Pharmetrics data used for this study no longer exists in this form as IMS has
created a new larger database called Pharmetrics Plus which includes a larger number of contributing
health plans. The database that includes the data used for this study is archived offsite and would
require data restoration to determine exact count.
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Figure 2.2. SCM Prescribed in 1 Year Following Diagnosis of Tobacco
Dependence, LifeLink Health Plan Claims Database (July 2010-June 2011)
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Background
Smoking increases the risk of numerous cancers, and continued smoking by
cancer patients and cancer survivors has been shown to have detrimental effects on
health. In a recent meta-analysis, Parsons et al reported that continued smoking was
associated with an increased risk of mortality, disease recurrence and development of
a second primary tumor in lung cancer patients.1 Moreover, continued smoking can
alter the pharmacokinetics of chemotherapeutic drugs, leading to lower serum
concentrations of the drug which may alter its therapeutic effect.2 In 2006, the
American Society for Clinical Oncology (ASCO) introduced the Quality Oncology
Practice Initiative (QOPI), which has become a key component of a measurement
system to promote quality cancer care. Quality measures include those related to
smoking cessation (SC) such as documentation of smoking status/tobacco in the past
year, smoking/tobacco use cessation counseling recommended to smokers/tobacco
users in the past year, and smoking/tobacco use cessation administered appropriately
in the past year.3 It’s important to note that patients with cancer who try to quit
smoking often do so without formal assistance which typically yields low success
rates.4
Further evidence of the need to foster SC in cancer patients is the issuance by the
National Comprehensive Cancer Network (NCCN) of clinical practice guidelines
focused on smoking cessation recommendations for patients with cancer. These
guidelines recommend that treatment plans for all smokers with cancer include
evidence based pharmacotherapy, behavior therapy and close follow-up with
retreatment as needed.5 However, information regarding the extent of employment of
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SC interventions, including SC medications (SCM), in cancer patients is lacking. Of
note, results of a survey by Warren et al report that physicians caring for lung cancer
patients believe that current smoking affects outcomes and that tobacco cessation is a
necessary part of clinical care, but few provide assistance to their patients as a routine
part of cancer care.6
Health-related databases, including claims databases, are an important data source
for research. One strength of these data is that they allow researchers to examine
medical care utilization as it occurs in routine clinical care or the “real world”. These
data sources can provide large study populations, long observation periods and allow
for examination of specific sub-populations.7 Though they are not without limitations,
adequately controlled observational studies using administrative claims data can
answer important questions in a relatively inexpensive and time-efficient manner.7
The utility of the LifeLink® database in studying SC interventions in patients with
smoking related co-morbidities was demonstrated by Make, et al in their study of
COPD in which they found that 82% of patients reported to be current smokers and
90% of current smokers in the Medicare population did not receive smoking cessation
interventions within 45 days of hospitalization for exacerbation of COPD.8
The study of SC treatment in patients with smoking related cancers in a national
population could identify potential gaps in quality care. The objective of this study
was to describe the epidemiology of SCM prescribing in newly identified tobacco
dependent patients with smoking related cancers and patient or provider characteristics
associated with its use.
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Methods
Design: This study employed a retrospective cross-sectional design using deidentified data from the LifeLink™ Health Plan Claims Database (formerly known as
Pharmetrics) which is comprised of commercial health plan information obtained from
managed care plans throughout the US. The database contains fully adjudicated
medical and pharmaceutical claims for over 68 million unique patients from over 102
health plans across the U.S. (approximately 16 million covered lives per year). The
database includes both inpatient and outpatient diagnoses (In International
Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] format)
and procedures (in Current Procedure Terminology [CPT-4] codes and Healthcare
Common Procedure Coding System [HCPCS] formats) as well as both retail and mail
order prescription records. Available data on prescription records include the National
Drug Code (NDC) as well as the quantity of the medication dispensed. Charge,
allowed and paid amounts are available for all services rendered, as well as dates of
service for all claims. Additional data elements include demographic variables (age,
gender, geographic region), product type (e.g., HMO, PPO), payer type (e.g.,
commercial, self-pay), provider specialty, and start and stop dates of health-plan
enrollment.
Sample Selection:
The sample consisted of patients aged 16-76 years newly identified as tobacco
dependent who had smoking related cancer as defined by presence of a diagnosis code
for tobacco use disorder and/or CPT code for tobacco cessation counseling, advice or
treatment (Appendix) during the index period July 2010 to June 2011 (index).
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Because of low cancer event rate and the assumption that diagnoses of smoking
related cancer and tobacco dependence within approximately 2 years of each other
were related, the identification period for a smoking related cancer diagnosis
(Appendix) was anytime in the study period January 2009 to June 2012. Patients with
ICD-9 or CPT codes related to tobacco dependence in the lookback period January
2009 through June 2010 were excluded (Figures 1, 2). Charlson Comorbidity Index
(CCI) scores for each patient were calculated using the algorithm develop by Quan, et
al., through identification of ICD-9 codes related to 17 co-morbidity categories in the
12 month period prior (pre-index) to and 12 month period after the index date
(including index date). Weights specific to each co-morbidity category were assigned
and the CCI score calculated; higher scores indicate greater co-morbidity.9
Statistical Analysis: Descriptive statistics were used to describe demographic and
clinical characteristics and frequency of prescription of SCM defined as 1 or more
claims for varenicline, bupropion SR or NRT during the study period January 1, 2009–
June 30, 2012. Demographic characteristics included patient age at index, gender,
geographic region of residence and insurance related factors such as payer type and
insurance product. Clinical characteristics included 12 month pre-index CCI score
and CCI categories. Provider characteristics included the practitioner type associated
with diagnosis of or counseling/advice for tobacco dependence. Patients were
categorized into one of two groups, those who were prescribed SCM at any time
during the study period and those who were not. Bivariate analyses including t-tests
for continuous variables and chi-square tests or Fisher’s Exact test for categorical
variables were used to analyze differences in patient characteristics. Assessment of
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factors associated with SCM prescription was performed by conducting a series of
univariate logistic regression equations. To qualify for multivariate logistic regression,
variables had to be associated with SCM prescription in the univariate analyses
(p<0.2) or be otherwise clinically important. Multivariate logistic regression was used
to assess relationships between the independent variables of patient and provider
characteristics and the dependent variable SCM prescription at any time during the
study period. The model was created using a backward elimination process and the
likelihood ratio test and AIC used to assess the model at each step, removing least
statistically significant covariates (p>0.05) with each iteration and evaluating
differences between full and reduced models for statistical significance. In advance of
model inclusion, multicollinearity among independent variables was assessed.
Multicollinearity was assessed by regressing independent variables against the
independent variable of patient age at index. Main effects and two factor interactions
of independent variables found significant in the model were assessed. The HosmerLemeshow test was used to assess goodness of fit of the final model. The measure of
effect is presented as an odds ratio with corresponding 95% confidence intervals. All
analyses were conducted using SAS® Version 9.4 (SAS Institute, Cary, NC) with
statistical significance defined as p <0.05. Analyses were performed using a 2-tailed
alpha of .05 and 95% confidence intervals calculated.
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Results
In total, 324 newly identified tobacco dependent patients with a smoking related
cancer were identified. Mean (SD) age at index was 58.51 years (10.38), 56.48% were
male and 66.05% resided in the Midwest. The most common payer type was
commercial in 75% of patients (Table 1). Mean (SD) pre-index CCI was 2.82 (±3.07)
and 43.21% were diagnosed with or counseled for tobacco cessation by a hospital
related department or practitioner. The most common pre-index Charlson
comorbidities were cancer in 56.48% of patients and COPD in 21.6% patients. Mean
(SD) CCI score in the 12 months following diagnosis was 5.08 (±3.19) and the
occurrence of the Charlson co-morbidity of cancer in the 12 months following
diagnosis (data not shown) was observed in all patients (Table 2). Lung cancer was
the most common tumor type in 79 patients (24.38%) (Table 3).
Of the diagnosed sample with a smoking related cancer, 46 patients (14.2%) were
treated with SCM during the study period. Of treated patients, mean (SD) age was
56.30 (8.94) years and 50% were male. Patients aged 50-64 were >3 times more
likely to be prescribed SCM than their younger or older counterparts (44.08% vs.
13.73% in age 20-49; 8.60% age ≥65 years). The majority of treated patients resided
in the East (22.58% vs. 16.82 in the Midwest; 3.85% in the South) (Table 1).
Compared to other tumor types, patients with lung cancer had the highest rate of SCM
prescription (21.52%) (Table 3).
In multivariate regression analysis, patients diagnosed by a hospital related
practitioner had lower odds of receiving SCM (OR 0.319, 95% CI 0.149-0.686). After
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multivariate analysis, age, patient gender, pre-index CCI score and payer type were
not significant.

Discussion
Tobacco smoking is known to increase the risk of numerous cancers and despite
declines in smoking rates over the past few decades, recent estimates suggest that
half of deaths in the US due to 12 cancer types are smoking related.9 Clinical practice
guidelines and quality measures encourage tobacco cessation efforts in patients with
cancer, and this study provides data that addresses the extent to which these
guidelines have been implemented.3,5 Our results suggest that 14.2% of tobacco
dependent patients with smoking related cancers were treated with SCM.
Due to paucity of data regarding rates of SCM use in cancer patients or the
general population of tobacco dependent persons and differences in study designs, it is
difficult to compare our findings to those of other studies. However, some insight into
the rate of SCM use in cancer patients is informed by a survey of physicians caring for
lung cancer patients who reported belief that tobacco cessation is a necessary part of
clinical care, but who also reported low rates of providing patients with assistance in
this regard.10 Of note, >20% reported rarely or never discussing medication options
with their patients during the initial visit, while approximately 15% reported always
doing so and almost one-third discussing medication options some of the time.10
However, it is not known if these physicians’ patients received SCM related
counseling from their non-oncology providers.
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Of note, compared to general medicine practitioners, tobacco dependence
diagnosis or procedure by a hospital related practitioner was associated with lower
odds of treatment with SCM (OR 0.319, 95% CI 0.149-0.686). Hospitalization is an
opportunity for patients to attempt to quit tobacco as they are likely to be in a smokefree environment and may be particularly motivated by an illness caused or
exacerbated by tobacco use.11 Patients can be encouraged to remain smoke free after
discharge and begin treatment in the hospital. In a meta-analysis of randomized
controlled trials of smokers hospitalized for a CVD diagnosis, a smoking cessation
intervention begun in the hospital and sustained for at least 1 month post-discharge,
increased cessation rates by 42% (RR: 1.42, 95% CI: 1.29–1.56) during the 6-12
months period post-discharge and starting NRT in hospital increased quit rates over
counseling alone.12 Furthermore, in a trial of smokers hospitalized with MI,
compared to usual care, intensive intervention with counseling and pharmacotherapy
increased cessation rates and reduced all-cause mortality and hospital readmission.13
Of note, it appears as though diagnosis of or counseling/advice for tobacco
dependence may have been co-incident with a tobacco related co-morbidity as mean
CCI score post-index was nearly twice that of the pre-index mean (5.08 vs. 2.82,
respectively) and the Charlson co-morbidity category of cancer was present in 56.48%
of patients prior to diagnosis and 100% post-index.
Finally, it is clear that tobacco cessation efforts need to be targeted earlier to
prevent clinical sequelae including cancer. Janjigian, et al found that 70% of NSCLC
patients had a smoking history of >15 pack years.14 Quitting smoking reduces cancer
risk and estimates are that five years after quitting, the risk of cancers of the mouth,
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throat, esophagus, and bladder is cut in half and after 10 years, the risk of dying from
lung cancer is about half that of a person who is still smoking.15 The risks of cancer of
the larynx (voice box) and pancreas are also reported to decrease.15
This study utilized data from medical and pharmacy claims which are collected
for billing and reimbursement purposes and which have inherent limitations. Data
entry errors at sites of care cannot be detected or corrected in data analysis. Although
data used in this study were collected from all U.S. census regions, due to geographic
biases, any unprojected geographic information may not be representative of the true
distribution. Finally, the small number of patients in some subgroups evaluated
precludes comparisons by statistical analysis and thus, results are descriptive in nature.
The requirement for continuous enrollment may bias the results due to lack of
ascertainment of mortality in a population of patients with higher mortality risk than
the general population. In general, expected cancer survival rates are longer when
disease is detected at earlier stages but ascertainment of cancer stage is not possible in
claims data. These results should be considered generalizable to an insured US
population with a smoking related cancer who have been diagnosed as tobacco
dependent or counseled/advised about smoking cessation and whose clinical or other
circumstances may be associated with survival.
It is also important to note that though patients were identified as smokers
through diagnosis or procedure codes, this provides no insight into readiness to quit
which is an important component of cessation attempts.11 Also, only prescription
versus over the counter (OTC) SCM could be captured and payment of a prescription
claim does not mean that a patient took the medication as prescribed. Because
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medications available OTC do not commonly exist in research databases, it is difficult
to estimate the extent to which OTC NRT is used. Results of an international survey
of smokers indicated that 68.3% of subjects self-report OTC NRT use. Of note, those
who obtained OTC NRT appeared more likely to discontinue in the first week of use
than those receiving NRT by prescription (23% vs. 13.4%, respectively.)16 These data
also do not represent those prescriptions that may have been written but not filled by
the patient. . Patients may have quit smoking, but clinical outcomes of this nature are
not ascertainable in administrative claims data. Thus, treatment rates may be
underestimated in this sample
Finally, misclassification of a cancer diagnosis as smoking related is possible, but
identification of tobacco dependence diagnosis or procedure was performed to ensure
that patients were smokers. Though not known, it is probable that a diagnosis of
tobacco dependence does not take place in all smokers so the sample may be
underrepresentative. Future research using a larger dataset could study this issue by
indexing on a smoking related cancer diagnosis and exploring use of SCM in these
patients. In addition, there is need for a prospective cohort study that would include
real time smoking data.
Despite limitations, this study adds important information regarding the use of
SCM in patients with cancer. Tobacco dependence or counseling/advice for smoking
cessation in these patients was likely coincident or following diagnosis of comorbidity
and earlier such intervention may be warranted. Diagnosis or counseling in a hospital
could capture patients at a time when cessation efforts such as initiating SCM have
been shown to be effective.
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Table 3.1. Rate of SCM Use by Demographic Characteristics among Tobacco
Dependent Patients with Smoking Related Cancer, LifeLink™ Health Plan
Claims Database, (July 2010-June 2011)
Total
(N =324 )
Age at index, years,
58.51 (10.38)
mean, (SD)
Age Category, No. (%)

No Rx for SCM in
study period (n=278)
58.88 (10.57)

Rx for SCM in
study period
(n=46)
56.30 (8.94)

p-value
0.1197

Ref=20-49
51 (15.74)

44 (86.27)

7 (13.73)

50-58

94 (29.01)

73 (77.66)

21 (22.34)

59-64

86 (26.54)

76 (88.37)

10 (21.74)

65-75

93 (28.70)

85 (91.40)

8 (8.60)

Female

141 (43.52)

118 (83.69)

23 (16.31)

Male

183 (56.48)

160 (87.43)

23 (12.57)

20-49

0.0464

Gender, No. (%)
0.3385

Patient Geographic Region, No. (%)
31 (9.57)

24 (77.42)

7 (22.58)

214 (66.05)

178 (83.18)

36 (16.82)

South

≤5 (1.54)

≤5 (≤100)

0

West

78 (24.07)

≤77 (≤98.72)

≤5 (≤6.41)

210 (84.34)

39 (15.66)

East
Midwest

<0.05

Product Type , No. (%)*
HMO

249 (76.85)

POS

114 (35.19)

0.3922
99 (86.84)

15 (13.16)

0.6928

202 (83.13)

41 (16.87)

0.0169

Payer Type, No (%)*
Commercial

243 (75.00)

Medicare

64 (19.75)

34 (53.13)

30 (46.88)

ns

Self-insured

47 (14.51)

41 (87.23)

6 (12.77)

0.7610

224 (83.90)
43 (16.10)
0.0333
267 (82.41)
Pharmacy Benefit
*Results presented only for SCM Rx counts >5
Rx=dispensed prescription, HMO=health maintenance organization, POS=place of service
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Table 3.2. Rate of SCM Use by Clinical Characteristics and Diagnosing Specialty
among Patients Tobacco Dependent Patients with Smoking Related Cancer,
LifeLink™ Health Plan Claims Database, (July 2010-June 2011)

2.94 (3.13)

Rx for SCM in
study period
(n=46)
2.09 (2.58)

99 (82.50)

21 (17.50)

100 (84.03)
79 (92.94)

19 (15.97)
6 (7.06)

0.0848

5.08 (3.18)

5.11 (3.29)

0.9537

79 (84.95)

14 (15.05)

91 (56.79)

79 (86.81)

12 (13.19)

CCI follow up 5-8, n (%)

72 (22.22)

64 (88.89)

8 (11.11)

CCI follow up 9-14 , n (%)

68 (20.99)

56 (82.35)

12 (17.65)

COPD

70 (21.60)

60 (85.71)

10 (14.29)

1.00

Cancer

183 (56.48)

163 (89.07)

20 (10.93)

0.0765

31 (9.57)

26 (83.87)

5 (16.13)

0.7861

Total
(N =324 )
Charlson Comorbidity Index (CCI),
mean, (SD) in 12 months pre-index
Pre-index CCI 0-1, n (%)
Pre-index CCI 2-3, n (%)

120 (37.04)
119 (36.73)

Pre-index CCI ≥4, n (%)

85 (26.23)

Charlson Comorbidity Index, mean,
(SD) during 1 year follow up period
CCI follow up 2, n (%)
CCI follow up 3-4 , n (%)

2.82 (3.07)

5.08 (3.19)
93 (28.70)

No Rx for SCM in study
period (n=278)

pvalue
0.0800

0.7150

Pre-index CCI categories* n=324

PVD

Diagnosing Specialty Type** No. (%)
General Medicine (GP/FP, Internal
106 (79.70)
27 (20.30)
0.0099
133 (41.05)
Med, NP, Ob/Gyn, Osteopath, PA)
Hospital Related Practitioner (surgical,
128 (91.43)
12 (8.57)
0.0153
140 (43.21)
ER, hospital, anesthesia, Orthopedics)
Specialist (e.g., cardiologist, pulm,onc,
endo, ent, gastro,ID,allergist, nephro,
59 (18.21)
1.00
8 (13.56)
neuro, ophth, optom,phys med,
51 (86.44)
podiatry, psych,rheum,urol)
Other (DME_HH, PT, RN,
12 (100)
0
12 (3.70)
SOC_WORK, MHSA_FAC)
Prescription with SCM in Study Period
46 (14.2%)
No. (%)
Prescription with SCM both pre-index
10 (0.31%)
and post-index No. (%)
*Results presented only for SCM counts >5
**Multiple specialties diagnosing the patient on the same date possible, Rx=dispensed prescription,
HMO=health maintenance organization, POS=place of se rvice, PPO=preferred provider organization,
HIV/AIDS=Human immunodeficiency Virus/Acquired Immunodeficiency Syndrome, GP=general
practice, FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology, PA=physician’s
assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine, ENT=ear, nose
& throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist, neuro=neurologist,
ophth=ophthalmologist, optom=optometrist, phys med= physical medicine, pscych=psychiatrist,
rheum=rheumatologist, urol=urologist, DM_HH=durable medical equipment/home health, PT=physical
therapist, RN=registered nurse, SOC_WORK=social worker, MHSA_FAC=mental health/substance
abuse facility
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Table 3.3. Rate of SCM Use by Tumor Type in Patients Diagnosed with Tobacco
Dependence, LifeLink™ Health Plan Claims Database (July 2010-June 2011)
(n=324)*
Tumor type
Any
Bladder
Colorectal cancer
Head and Neck
Kidney
Lung

324 (100)
50 (15.43)
59 (18.21)
50 (15.43)
40 (12.35)
79 (24.38)

No SCM Rx
(n=278)
278 (85.80)
43 (86.00)
53 (89.83)
44 (88.00)
34 (85.00)
62 (78.48)

*Results presented only for SCM Rx counts >5
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SCM Rx
n=46)
46 (14.20)
7 (14.00)
6 (10.17)
6 (12.00)
6 (15.00)
17 (21.52)

p-value
0.1116
0.9653
0.3270
0.6283
0.8766
0.0320

Table 3.4. Summary of Logistic Regression Analysis of Predictors of Treatment
with SCM in Tobacco Dependent Patients with Smoking Related Cancer: Odds
Ratios and 95% Confidence Intervals
Independent variable

Odds Ratio

95% Wald CI

p-value

Age 50-58 years
(reference = 20-49 years)
Age 59-64 years
(reference = 20-49 years)
Age >65 years (reference = 20-49 years)

1.810

0.694-4.725

0.2254

0.828

0.288 -2.384

0.7272

0.539

0.179 – 1.618

0.2702

Diagnosis by disease specialist,
pediatrician, non-physician
Diagnosis by hospital related practitioner

0.4670

0.232 – 1.445

0.2415

0.319

0.149 – 0.686

0.0034

Hosmer- Lemeshow Goodness of Fit Test p = 0.9016
CI=confidence interval
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Figure 3.1. Sample Selection Diagram– Tobacco Dependent Patients with
Smoking Related Cancers and Treatment with SCM (January 2009-June
2012)
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Figure 3.2. Sample Selection Flow– Tobacco Dependent Patients with Smoking
Related Cancers and Treatment with SCM (January 2009-June2012)……………
LifeLink™ Health Plan Claims Database enrolled patients: N=18,400,000 as of August 2012*
Continuously enrolled patients January 2009 – June 2012
Patients aged 16-76 identified as having any tobacco related diagnoses or procedure, SCM or smoking
related cancers
n = 117,695
Patients identified as having any tobacco related diagnoses or procedures or smoking related cancers
(Patient count without smoking cessation treatment)
n=80,486
Patients enrolled January 2009 to June 2012 with a diagnosis or procedure indicating tobacco
dependence (Patient count without smoking related cancer)
n=77,736
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010
and June 2011 (index)
n=18,619
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 and June
2011 with claims activity throughout the study period (January 2009 – June 2012)
n=16,417
Patients with a diagnosis or procedure indicating tobacco dependence between July 2010 and
June 2011 with claims activity throughout the study period (January 2009 - June 2012) and a diagnosis
of smoking related cancer (January 2009 - June 2012)
n=324
Treatment with SCM in pre or post index periods
(January 2009-June 2012)
n = 46

No Treatment with SCM in pre or post
index periods
(January 2009-June 2012)
n = 278

*Closest estimate for continuously enrolled patients during the study period is 18.4MM patients as of
August 2012. Enrollment is subject to change quarterly as updates are received from contributing
health plans. Largest changes are typically seen at year beginning when patients may leave a health
plan and join another. The data used for this study has been merged into a new larger database called
Pharmetrics Plus which includes a larger number of contributing health plans. The database that
includes the data used for this study is archived and would require data restoration to determine exact
count.
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CONCLUSION

The 3 studies presented herein provide insight into the utility of using
administrative claims data to study patients who are tobacco dependent and their
treatment with SCM. Taken in their entirety, these studies’ findings contribute certain
apparent overarching themes and other important observations.

Keeping in mind the stated limitation of 18 month claims history and possibility
that patients may have been diagnosed, counseled or treated for tobacco dependence
prior to index in these studies, it seems apparent that the health system is identifying patients as tobacco dependent co-incident with identification of other co-morbidity.
This is evident in the first manuscript through the 34% change in CCI from the pre- to
the post-index period and in the third study which observed a near doubling of CCI in
cancer patients after newly being identified or counseled as tobacco dependent. As
stated, early intervention and management of tobacco dependence is likely the best
strategy to aid patients in what is likely to be multiple attempts to quit smoking.
The second theme is related to practitioner type diagnosing or counseling
patients. Diagnosis or counseling by a hospital related practitioner was associated
with reduced likelihood of SCM treatment as an outpatient overall and in patients with
smoking related cancer. Joint Commission core measures include counseling for
tobacco dependence in inpatients, but these efforts may not be continued after patients
are discharged from the hospital. However, it is not known if patients obtained OTC
NRT following discharge or if the important factor of change readiness to embark on a
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quit effort was present. Though these variables are not observable in claims data,
perhaps identification of patients in this manner could serve as indicators for future
follow up after discharge. Similarly, diagnosis by a therapeutic area specialist was
associated with lower likelihood of SCM prescription and it has been recognized in the
literature that management of tobacco dependence can be a major contributor to risk of
events often managed by therapeutic area specialists, e.g., cardiologists and
oncologists, and that specialists are in unique position to aid patients in their quit
efforts. Management of smoking cessation should not be considered a primary care
issue, but an opportunity for intervention at any health care professional interaction.
Another theme is consideration of baseline co-morbidity and relationship to use
of SCM. In the first study, use of SCM was low in those with cancer or MI at baseline
and patients with cancer diagnosis at baseline had reduced odds of SCM prescription.
Interestingly, this finding exists in parallel to the finding of reduced odds of SCM use
in patients diagnosed or counseled by therapeutic area specialists. Of note, patients
with HIV/AIDS had the highest rates of SCM prescription which is encouraging given
the additional risk of smoking in these patients, but generalizability to a routine
Medicaid population from these data obtained from commercial health plans must be
considered.
The premature discontinuation rate observed in the second study exceeded 90%
and studies exist that have varied designs and descriptions of the relationship of
duration of therapy and quit outcomes with some studies finding quitting success with
shorter durations than 12 weeks and others suggesting that longer durations of SCM
therapy yields better quit outcomes. Considering that patients may experience reduced
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cravings and nicotine withdrawal symptoms relatively early in SCM therapy,
consideration should be given to counseling patients at the outset and throughout
therapy regarding their possible perception that they no longer need therapy
juxtaposed with information from labeled instructions describing recommended
duration of use.
Differences in SCM use by age were also observed with the youngest and oldest
patients being less likely to receive SCM prescription and patients over age 50 years
having lower likelihood of premature discontinuation. Consideration of differences in
readiness to change by patients who may have yet experienced a smoking related
comorbidity and in those who may be resistant to changing longstanding behaviors is
important. Recent action by the American Academy of Pediatrics suggests
consideration of SCM use in younger people depending on their readiness to change
and extent of tobacco dependence. Moreover, older patients can still be motivated to
change and advanced age should not serve as a barrier to use of SCM.
Lastly, certain factors not studied here are important to consider for future study
including combination use of SCM agents, exploration of mental health factors related
to tobacco dependence diagnosis or counseling and SCM use and exploration of larger
datasets with longer study periods.
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APPENDICES
Table A.1.1 Tobacco Dependence Related Diagnosis and Procedure Codes
Diagnosis or
Procedure Code
ICD-9

HCPCS/CPT

Code and Description
305.1 Tobacco use disorder
989.84 Toxic effect of other substances, chiefly nonmedicinal as to source, tobacco
649.0x Tobacco use disorder complicating pregnancy, childbirth, or puerperium
V1582 History of tobacco use (personal history of tobacco use)
99406 Smoking and tobacco-use cessation counseling visit; intermediate, greater
than 3 minutes up to 10 minutes.
99407 Smoking and tobacco-use cessation counseling visit; intensive, greater than
10 minutes.
S9075 Smoking Cessation Treatment
S9453 Smoking Cessation Classes, non-physician provider, per session
1032F Current tobacco smoker or currently exposed to secondhand smoke (asthma)
1033F Current tobacco non-smoker and not currently exposed to secondhand
smoke (asthma)
1034F Tobacco - current smoker
1035F Current smokeless tobacco user (chew, snuff)
4000F Tobacco use cessation intervention, counseling
4001F Tobacco use cessation intervention, pharmacologic therapy
4004F Patient screened for tobacco use and received tobacco cessation
intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user
C9801 Smoking and tobacco cessation counseling visit for the asymptomatic
patient intermediate, greater than 3 minutes, up to 10
C9802 Smoking and tobacco cessation counseling visit for the asymptomatic
patient intensive, greater than 10 minutes
G0375 Smoking and tobacco use cessation counseling visit; intermediate, greater
than 3 minutes up to 10 minutes
G0376 Smoking and tobacco use cessation counseling visit; intensive, greater
than 10 minutes
G0436 Smoking and tobacco cessation counseling visit for the asymptomatic
patient; intermediate, greater than 3 minutes, up to 10 minutes
G0437 Smoking and tobacco cessation counseling visit for the asymptomatic
patient; intensive, greater than 10 minutes
G8402 Tobacco (smoke) use cessation intervention, counseling
G8403 Tobacco (smoke) use cessation intervention not counseled
G8453 Tobacco use cessation intervention, counseling
G8454 Tobacco use cessation intervention not counseled, reason not specified
G8455 Current tobacco smoker
G8456 Current smokeless tobacco user
G8686 Currently a tobacco smoker or current exposure to secondhand smoke
G8688 Currently a smokeless tobacco user (eg, chew, snuff) and no exposure to
secondhand smoke
G8690 Current tobacco smoker or current exposure to secondhand smoke
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Table A.1.2. Charlson Co-morbidity Index Codes
Co-morbidity

Codes

Chronic pulmonary disease

490.x-496.x, 500.x-505.x, 416.8, 416.9, 506.4, 508.1, 508.8

Diabetes without chronic
complications
Any malignancy, including
lymphoma and leukemia,
except neoplasm of skin
Mild liver disease

250.0-250.3

Peripheral Vascular Disease
Cerebrovascular Disease
Diabetes with chronic
complications
Rhuematic Disease
Congestive Heart Failure

140.x-165.x, 170.x-172.x, 174.x-176.x, 179.x, 180.x-195.x, 200.x208.x
070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9,
570.x, 571.x, 573.3, 573.4, 573.8, 573.9, V42.7
440.x, 441.x, 0930, 4373, 443.1, 443.2, 443.8, 443.9, 447.1, 557.1,
557.9, V43.4
430.x-438.x, 362.34
250.4-250.9
446.5, 710.0-710.4, 714.0- 714.2, 714.8, 725
428.x,425.4-425.9, 398.91, 402.91, 402.11, 404.01, 404.03, 404.11,
404.13, 404.91, 404.93

Myocardial infarction
Renal Disease
Metastatic cancer
Hemiplegia or paraplegia

410.x, 412.x
403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92,
404.93, 582.x, 585.x, 586.x V56.x
583.0-583.2, 583.4, 583.6-583.7, 588.0, V420, V451
196.x-199.x
334.1, 342.x, 343.x, 344.0-344.6, 344.9

Peptic ulcer disease
Moderate to severe liver
disease
HIV/AIDS

531.x-534.x
456.0-456.2, 572.2-572.4, 572.8
042.x-044.x

Dementia

290.x, 294.1, 331.2
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Table A.1.3. Select CCI categories Pre-index and During Follow-up Periods –
All diagnosed patients (n=15000), LifeLink™ Health Plan Claims Database
(July 2010-June 2011)
CCI
Category,
No. (%)

During 12
months
pre-index
only

In 1yr follow
up only

Both Pre-index and
Follow-up

Difference

p - value

COPD

705 (4.70)

1657 (11.05)

1187 (7.91)

135%

<0.0001

Diabetes

170 (1.13)

412 (2.75)

1130 (7.53)

142%

<0.0001

Cancer

107 (0.71)

314 (2.09)

533 (3.55)

193%

<0.0001

PVD

179 (1.19)

394 (2.63)

226 (1.51)

120%

<0.0001

CVD

183 (1.22)

394 (2.63)

163 (1.09)

115%

<0.0001

CHF

82 (0.55)

215 (1.43)

144 (0.96)

162%

<0.0001

MI

88 (0.59)

235 (1.57)

90 (0.60)

157%

<0.0001

Metastatic
cancer

36 (0.24)

108 (0.72)

34 (0.23)

200%

<0.0001
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Table A.1.4. Results of Test for Multicollinearity Among Independent Variables
Selected for Multivariate Logistic Regression – Predictors of SCM Use in
Tobacco Dependent Patients, LifeLink™ Health Plan Claims Database (July
2010-June 2011)
Regression Against Patient Age at Index
Independent Variable
Variance Inflation Factor
Payer Type Medicare Supplemental
1.072
Payer Type Medicare Advantage
1.367
Payer Type Medicaid
1.994
Payer Type Self-insured
1.665
Payer Type Commercial
2.669
Diagnosing Practitioner Type
4.399
General Medicine
Diagnosing Practitioner Type
3.808
Hospital Related
Diagnosing Practitioner Type
1.097
Pediatrics
Diagnosing Practitioner Type
1.971
Therapeutic Area Specialist
Diagnosing Practitioner Type Other
1.161
CHF diagnosis in 12 months pre1.087
index
MI diagnosis in 12 months pre1.065
index
Cancer diagnosis in 12 months pre1.025
index
Diabetes diagnosis in 12 months
1.208
pre-index
Renal Disease diagnosis in 12
1.215
months pre-index
Mild liver disease diagnosis in 12
1.068
months pre-index
HIV-AIDS diagnosis in 12 months
1.020
pre-index
Ulcer diagnosis in 12 months pre1.004
index
CHF diagnosis in 12 months pre1.005
index
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Condition Index
1.522
1.736
1.774
1.845
1.868
1.900
1.912
1.922
1.940
1.952
1.992
2.020
2.065
2.129
2.198
2.318
2.546
7.550
13.569

Table A.2.1. Results of Test for Multicollinearity Among Independent Variables
Selected for Multivariate Logistic Regression Model – Predictors of Premature
SCM Discontinuation
Regression Against Patient Age at Index
Independent Variable

Variance Inflation Factor

Condition Index

Payer Type Medicare Supplemental

1.205

1.637

Payer Type Medicare Advantage

1.064

1.908

Payer Type Medicaid

2.373

1.951

Payer Type Self-insured

2.187

2.123

Payer Type Commercial

2.559

2.147

Insurance Product HMO

1.630

2.157

Insurance Product PPO

2.420

2.212

Insurance Product POS

1.710

2.270

Insurance Product Consumer
Directed

1.028

2.392

Insurance Product Indemnity

1.121

2.460

Diagnosing Practitioner Type
General Medicine

3.412

3.198

Diagnosing Practitioner Type
Therapeutic Area Specialist

1.817

4.404

Diagnosing Practitioner Type
Hospital Related

2.540

6.529

Diagnosing Practitioner Type
Pediatrics

1.111

9.487

Diagnosing Practitioner Type Other

1.185

15.514
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. Results of Test for Multicollinearity Among Independent Variables
Selected for Multivariate Logistic Regression Model - Predictors of Repeat
Treatment with SCM
Table A.2.2.

Regression Against Patient Age at Index
Independent Variable

Variance Inflation Factor

Condition Index

Insurance Product HMO

1.444

1.706

Insurance Product PPO

1.084

1.824

Insurance Product POS

1.496

1.837

Insurance Product Consumer
Directed

1.022

1.864

Insurance Product Indemnity

1.062

1.887

Diagnosing Practitioner Type
General Medicine

3.393

1.956

Diagnosing Practitioner Type
Therapeutic Area Specialist

1.784

2.000

Diagnosing Practitioner Type
Hospital Related

2.536

2.486

Diagnosing Practitioner Type
Pediatrics

1.108

5.586

Diagnosing Practitioner Type Other

1.177

11.413
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Table A.3.1. ICD-9 Codes and Descriptions – Smoking Related Cancers
TUMOR TYPE

TUMOR
SUB-TYPE

CODE

CODE

Head & Neck Cancer

140

140

Malignant neoplasm of lip

Head & Neck Cancer

1400

140.0

Head & Neck Cancer

1401

140.1

Head & Neck Cancer

1403

140.3

Head & Neck Cancer

1404

140.4

Head & Neck Cancer

1405

140.5

Head & Neck Cancer

1406

140.6

Head & Neck Cancer

1408

140.8

Head & Neck Cancer

1409

140.9

Head & Neck Cancer

141

141

Head & Neck Cancer

1410

141.0

Head & Neck Cancer

1411

141.1

Head & Neck Cancer

1412

141.2

Head & Neck Cancer

1413

141.3

Head & Neck Cancer

1414

141.4

Head & Neck Cancer

1415

141.5

Head & Neck Cancer

1416

141.6

Head & Neck Cancer

1418

141.8

Head & Neck Cancer

1419

141.9

Head & Neck Cancer
Head & Neck Cancer

143
1430

143
143.0

Head & Neck Cancer

1431

143.1

Head & Neck Cancer

1438

143.8

Head & Neck Cancer

1439

143.9

Malignant neoplasm of
upper lip, vermilion border
Malignant neoplasm of
lower lip, vermilion border
Malignant neoplasm of
upper lip, inner aspect
Malignant neoplasm of
lower lip, inner aspect
Malignant neoplasm of lip,
inner aspect, unspecified as
to upper or lower
Malignant neoplasm of
commissure of lip
Malignant neoplasm of
other sites of lip
Malignant neoplasm of lip,
vermilion border,
unspecified as to upper or
lower
Malignant neoplasm of
tongue
Malignant neoplasm of base
of tongue
Malignant neoplasm of
dorsal surface of tongue
Malignant neoplasm of tip
and lateral border of tongue
Malignant neoplasm of
ventral surface of tongue
Malignant neoplasm of
anterior two-thirds of
tongue, part unspecified
Malignant neoplasm of
junctional zone of tongue
Malignant neoplasm of
lingual tonsil
Malignant neoplasm of
other sites of tongue
Malignant neoplasm of
tongue, unspecified site
Malignant neoplasm of gum
Malignant neoplasm of
upper gum
Malignant neoplasm of
lower gum
Malignant neoplasm of
other sites of gum
Malignant neoplasm of
gum, unspecified site
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DESCRIPTION

TUMOR TYPE

TUMOR
SUB-TYPE

CODE

CODE

Head & Neck Cancer

144

144

Head & Neck Cancer

1440

144.0

Head & Neck Cancer

1441

144.1

Head & Neck Cancer

1448

144.8

Head & Neck Cancer

1449

144.9

Head & Neck Cancer

145

145

Head & Neck Cancer

1450

145.0

Head & Neck Cancer

1451

145.1

Head & Neck Cancer

1452

145.2

Head & Neck Cancer

1453

145.3

Head & Neck Cancer

1454

145.4

Head & Neck Cancer

1455

145.5

Head & Neck Cancer

1456

145.6

Head & Neck Cancer

1458

145.8

Head & Neck Cancer

1459

145.9

Head & Neck Cancer

146

146

Head & Neck Cancer

1460

146.0

Head & Neck Cancer

1461

146.1

Head & Neck Cancer

1462

146.2

Head & Neck Cancer

1463

146.3

Head & Neck Cancer

1464

146.4

Head & Neck Cancer

1465

146.5

Head & Neck Cancer

1466

146.6

Head & Neck Cancer

1467

146.7
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DESCRIPTION
Malignant neoplasm of floor
of mouth
Malignant neoplasm of
anterior portion of floor of
mouth
Malignant neoplasm of
lateral portion of floor of
mouth
Malignant neoplasm of
other sites of floor of mouth
Malignant neoplasm of floor
of mouth, part unspecified
Malignant neoplasm of
other and unspecified parts
of mouth
Malignant neoplasm of
cheek mucosa
Malignant neoplasm of
vestibule of mouth
Malignant neoplasm of hard
palate
Malignant neoplasm of soft
palate
Malignant neoplasm of
uvula
Malignant neoplasm of
palate, unspecified
Malignant neoplasm of
retromolar area
Malignant neoplasm of
other specified parts of
mouth
Malignant neoplasm of
mouth, unspecified site
Malignant neoplasm of
oropharynx
Malignant neoplasm of
tonsil
Malignant neoplasm of
tonsillar fossa
Malignant neoplasm of
tonsillar pillars (anterior)
(posterior)
Malignant neoplasm of
vallecula
Malignant neoplasm of
anterior aspect of epiglottis
Malignant neoplasm of
junctional region of
oropharynx
Malignant neoplasm of
lateral wall of oropharynx
Malignant neoplasm of

TUMOR TYPE

TUMOR
SUB-TYPE

CODE

CODE

Head & Neck Cancer

1468

146.8

Head & Neck Cancer

1469

146.9

Head & Neck Cancer

147

147

Head & Neck Cancer

1470

147.0

Head & Neck Cancer

1471

147.1

Head & Neck Cancer

1472

147.2

Head & Neck Cancer

1473

147.3

Head & Neck Cancer

1478

147.8

Head & Neck Cancer

1479

147.9

Head & Neck Cancer

148

148

Head & Neck Cancer

1480

148.0

Head & Neck Cancer

1481

148.1

Head & Neck Cancer

1482

148.2

Head & Neck Cancer

1483

148.3

Head & Neck Cancer

1488

148.8

Head & Neck Cancer

1489

148.9

Head & Neck Cancer

149

149

Head & Neck Cancer

1490

149.0

Head & Neck Cancer

1491

149.1

Head & Neck Cancer

1498

149.8
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DESCRIPTION
posterior wall of oropharynx
Malignant neoplasm of
other specified sites of
oropharynx
Malignant neoplasm of
oropharynx, unspecified site
Malignant neoplasm of
nasopharynx
Malignant neoplasm of
superior wall of
nasopharynx
Malignant neoplasm of
posterior wall of
nasopharynx
Malignant neoplasm of
lateral wall of nasopharynx
Malignant neoplasm of
anterior wall of
nasopharynx
Malignant neoplasm of
other specified sites of
nasopharynx
Malignant neoplasm of
nasopharynx, unspecified
site
Malignant neoplasm of
hypopharynx
Malignant neoplasm of
postcricoid region of
hypopharynx
Malignant neoplasm of
pyriform sinus
Malignant neoplasm of
aryepiglottic fold,
hypopharyngeal aspect
Malignant neoplasm of
posterior hypopharyngeal
wall
Malignant neoplasm of
other specified sites of
hypopharynx
Malignant neoplasm of
hypopharynx, unspecified
site
Malignant neoplasm of
other and ill-defined sites
within the lip, oral cavity,
and pharynx
Malignant neoplasm of
pharynx, unspecified
Malignant neoplasm of
Waldeyer's ring
Malignant neoplasm of

TUMOR TYPE

TUMOR
SUB-TYPE

Head & Neck Cancer

CODE

CODE

1499

149.9

Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other

Esophageal
Cancer
Esophageal
Cancer
Esophageal
Cancer
Esophageal
Cancer
Esophageal
Cancer
Esophageal
Cancer
Esophageal
Cancer
Esophageal
Cancer

150

150

1500

150.0

1501

150.1

1502

150.2

1503

150.3

1504

150.4

1505

150.5

1508

150.8

Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other
Gastrointestinal Cancers;
Other

Esophageal
Cancer
Stomach
Cancer
Stomach
Cancer
Stomach
Cancer
Stomach
Cancer

1509

150.9

151

151

1513

151.3

1514

151.4

1515

151.5

Gastrointestinal Cancers;
Other

Stomach
Cancer

1516

151.6

Gastrointestinal Cancers;
Other

Stomach
Cancer

1518

151.8

Gastrointestinal Cancers;
Other
Colorectal Cancer (CRC)

Stomach
Cancer

1519

151.9

153

153

Colorectal Cancer (CRC)

1530

153.0

Colorectal Cancer (CRC)

1531

153.1

Colorectal Cancer (CRC)

1532

153.2

Colorectal Cancer (CRC)

1533

153.3

Colorectal Cancer (CRC)

1534

153.4
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DESCRIPTION
other sites within the lip and
oral cavity
Malignant neoplasm of illdefined sites of lip and oral
cavity
Malignant neoplasm of
esophagus
Malignant neoplasm of
cervical esophagus
Malignant neoplasm of
thoracic esophagus
Malignant neoplasm of
abdominal esophagus
Malignant neoplasm of
upper third of esophagus
Malignant neoplasm of
middle third of esophagus
Malignant neoplasm of
lower third of esophagus
Malignant neoplasm of
other specified part of
esophagus
Malignant neoplasm of
esophagus, unspecified site
Malignant neoplasm of
stomach
Malignant neoplasm of
fundus of stomach
Malignant neoplasm of
body of stomach
Malignant neoplasm of
lesser curvature of stomach,
unspecified
Malignant neoplasm of
greater curvature of
stomach, unspecified
Malignant neoplasm of
other specified sites of
stomach
Malignant neoplasm of
stomach, unspecified site
Malignant neoplasm of
colon
Malignant neoplasm of
hepatic flexure
Malignant neoplasm of
transverse colon
Malignant neoplasm of
descending colon
Malignant neoplasm of
sigmoid colon
Malignant neoplasm of
cecum

TUMOR TYPE

TUMOR
SUB-TYPE

CODE

CODE

Colorectal Cancer (CRC)

1535

153.5

Colorectal Cancer (CRC)

1536

153.6

Colorectal Cancer (CRC)

1537

153.7

Colorectal Cancer (CRC)

1538

153.8

Colorectal Cancer (CRC)

1539

153.9

Colorectal Cancer (CRC)

154

154

Colorectal Cancer (CRC)

1540

154.0

Colorectal Cancer (CRC)

1541

154.1

Colorectal Cancer (CRC)

1548

154.8

Pancreatic Cancer

157

157

Pancreatic Cancer

1570

157.0

Pancreatic Cancer

1571

157.1

Pancreatic Cancer

1572

157.2

Pancreatic Cancer

1573

157.3

Pancreatic Cancer

1574

157.4

Pancreatic Cancer

1578

157.8

Pancreatic Cancer

1579

157.9

Head & Neck Cancer

160

160

Head & Neck Cancer

1600

160.0

Head & Neck Cancer

1601

160.1

Head & Neck Cancer

1602

160.2

Head & Neck Cancer

1603

160.3

Head & Neck Cancer

1604

160.4
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DESCRIPTION
Malignant neoplasm of
appendix
Malignant neoplasm of
ascending colon
Malignant neoplasm of
splenic flexure
Malignant neoplasm of
other specified sites of large
intestine
Malignant neoplasm of
colon, unspecified site
Malignant neoplasm of
rectum, rectosigmoid
junction, and anus
Malignant neoplasm of
rectosigmoid junction
Malignant neoplasm of
rectum
Malignant neoplasm of
other sites of rectum,
rectosigmoid junction, and
anus
Malignant neoplasm of
pancreas
Malignant neoplasm of head
of pancreas
Malignant neoplasm of
body of pancreas
Malignant neoplasm of tail
of pancreas
Malignant neoplasm of
pancreatic duct
Malignant neoplasm of
islets of Langerhans
Malignant neoplasm of
other specified sites of
pancreas
Malignant neoplasm of
pancreas, part unspecified
Malignant neoplasm of
nasal cavities, middle ear,
and accessory sinuses
Malignant neoplasm of
nasal cavities
Malignant neoplasm of
auditory tube, middle ear,
and mastoid air cells
Malignant neoplasm of
maxillary sinus
Malignant neoplasm of
ethmoidal sinus
Malignant neoplasm of
frontal sinus

TUMOR TYPE

TUMOR
SUB-TYPE

CODE

CODE

Head & Neck Cancer

1605

160.5

Head & Neck Cancer

1608

160.8

Head & Neck Cancer

1609

160.9

Head & Neck Cancer

161

161

Head & Neck Cancer

1610

161.0

Head & Neck Cancer

1611

161.1

Head & Neck Cancer

1612

161.2

Head & Neck Cancer

1613

161.3

Head & Neck Cancer

1618

161.8

Head & Neck Cancer

1619

161.9

Lung Cancer

162

162

Lung Cancer

1620

162.0

Lung Cancer

1622

162.2

Lung Cancer

1623

162.3

Lung Cancer

1624

162.4

Lung Cancer

1625

162.5

Lung Cancer

1628

162.8

Lung Cancer

1629

162.9

Malignant Neoplasms, Other

163

163

Malignant Neoplasms, Other

1630

163.0

Malignant Neoplasms, Other

1631

163.1

Malignant Neoplasms, Other

1638

163.8
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DESCRIPTION
Malignant neoplasm of
sphenoidal sinus
Malignant neoplasm of
other sites of nasal cavities,
middle ear, and accessory
sinuses
Malignant neoplasm of site
of nasal cavities, middle ear,
and accessory sinus,
unspecified site
Malignant neoplasm of
larynx
Malignant neoplasm of
glottis
Malignant neoplasm of
supraglottis
Malignant neoplasm of
subglottis
Malignant neoplasm of
laryngeal cartilages
Malignant neoplasm of
other specified sites of
larynx
Malignant neoplasm of
larynx, unspecified site
Malignant neoplasm of
trachea, bronchus, and lung
Malignant neoplasm of
trachea
Malignant neoplasm of
main bronchus
Malignant neoplasm of
upper lobe, bronchus, or
lung
Malignant neoplasm of
middle lobe, bronchus, or
lung
Malignant neoplasm of
lower lobe, bronchus, or
lung
Malignant neoplasm of
other parts of bronchus or
lung
Malignant neoplasm of
bronchus and lung,
unspecified site
Malignant neoplasm of
pleura
Malignant neoplasm of
parietal pleura
Malignant neoplasm of
visceral pleura
Malignant neoplasm of

TUMOR TYPE

TUMOR
SUB-TYPE

CODE

CODE

Malignant Neoplasms, Other

1639

163.9

Malignant Melanoma

1720

172.0

Basal Cell Carcinoma

17301

173.01

180

180

1800

180.0

1801

180.1

1808

180.8

1809

180.9

Ovarian Cancer

183

183

Ovarian Cancer

1830

183.0

Gynecological Cancer

1838

183.8

Gynecological Cancer

1839

183.9

Bladder Cancer

188

188

Bladder Cancer

1880

188.0

Bladder Cancer

1881

188.1

Bladder Cancer

1882

188.2

Bladder Cancer

1883

188.3

Bladder Cancer

1884

188.4

Bladder Cancer

1885

188.5

Bladder Cancer

1886

188.6

Bladder Cancer

1887

188.7

Bladder Cancer

1888

188.8

Gynecological Cancer
Gynecological Cancer
Gynecological Cancer
Gynecological Cancer
Gynecological Cancer

Cervical
Cancer
Cervical
Cancer
Cervical
Cancer
Cervical
Cancer
Cervical
Cancer
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DESCRIPTION
other specified sites of
pleura
Malignant neoplasm of
pleura, unspecified site
Malignant melanoma of
skin of lip
Basal Cell Carcinoma Of
Skin Of Lip
Malignant neoplasm of
cervix uteri
Malignant neoplasm of
endocervix
Malignant neoplasm of
exocervix
Malignant neoplasm of
other specified sites of
cervix
Malignant neoplasm of
cervix uteri, unspecified site
Malignant neoplasm of
ovary and other uterine
adnexa
Malignant neoplasm of
ovary
Malignant neoplasm of
other specified sites of
uterine adnexa
Malignant neoplasm of
uterine adnexa, unspecified
site
Malignant neoplasm of
bladder
Malignant neoplasm of
trigone of urinary bladder
Malignant neoplasm of
dome of urinary bladder
Malignant neoplasm of
lateral wall of urinary
bladder
Malignant neoplasm of
anterior wall of urinary
bladder
Malignant neoplasm of
posterior wall of urinary
bladder
Malignant neoplasm of
bladder neck
Malignant neoplasm of
ureteric orifice
Malignant neoplasm of
urachus
Malignant neoplasm of
other specified sites of

TUMOR TYPE

CODE

CODE

Bladder Cancer

1889

188.9

Kidney Cancer, Other

189

189

Renal Cancer

1890

189.0

Kidney Cancer, Other

1891

189.1

Kidney Cancer, Other

1892

189.2

Genitourinary Cancer

1893

189.3

Genitourinary Cancer

1894

189.4

Genitourinary Cancer

1898

189.8

Genitourinary Cancer

1899

189.9

2050

205.0

20500

205.00

Acute myeloid leukemia
without mention of
remission

20501

205.01

Acute myeloid leukemia in
remission

20502

205.02

Acute myeloid leukemia, in
relapse

20921

209.21

20923

209.23

20924

209.24

Malignant carcinoid tumor
of the bronchus and lung
Malignant carcinoid tumor
of the stomach
Malignant carcinoid tumor
of the kidney

Leukemia

Leukemia

Leukemia

Leukemia

TUMOR
SUB-TYPE

Acute
Myeloid
Leukemia
(AML)
Acute
Myeloid
Leukemia
(AML)
Acute
Myeloid
Leukemia
(AML)
Acute
Myeloid
Leukemia
(AML)

Endocrine Cancer
Endocrine Cancer
Endocrine Cancer

Stomach
Cancer
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DESCRIPTION
bladder
Malignant neoplasm of
bladder, part unspecified
Malignant neoplasm of
kidney and other and
unspecified urinary organs
Malignant neoplasm of
kidney, except pelvis
Malignant neoplasm of
renal pelvis
Malignant neoplasm of
ureter
Malignant neoplasm of
urethra
Malignant neoplasm of
paraurethral glands
Malignant neoplasm of
other specified sites of
urinary organs
Malignant neoplasm of
urinary organ, site
unspecified
Acute myeloid leukemia

Table A.3.2. Results of Test for Multicollinearity Among Independent Variables
Selected for Multivariate Logistic Regression – Predictors of SCM Use in
Tobacco Dependent Patients with Smoking Related Cancer
Regression Against Patient Age at Index
Independent Variable
Variance Inflation Factor
Charlson Co-morbidity Index Score
1.067
in 12 months pre-index
Insurance Product HMO
1.136
Payer Type Commercial
2.896
Payer Type Medicaid
1.747
Payer Type Medicare Supplemental
1.187
Payer Type Medicare Advantage
1.960
Payer Type Self-insured
1.859
Diagnosing Practitioner Type
3.581
Hospital Related
Diagnosing Practitioner Type
3.632
General Medicine
Diagnosing Practitioner Type
2.254
Therapeutic Area Specialist
Diagnosing Practitioner Type Other
1.400
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Condition Index
1.889
1.991
2.111
2.188
2.321
2.665
2.754
3.177
5.247
7.809
14.917
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